

Curriculum Vitae
Daniel B. Jernigan, MD MPH
June 2024

Contact Information: Daniel B. Jernigan, MD MPH
Director, National Center for Emerging and Zoonotic Infectious Diseases
Captain (Retired), US Public Health Service
Centers for Disease Control and Prevention
1600 Clifton Road, [REDACTED],
Atlanta, GA 30329
E-mail [REDACTED]
[REDACTED], office; [REDACTED], mobile
[REDACTED], 24/7 Emergency Operations Center

Education and Training

Post-Graduate

- 1997 **Preventive Medicine Residency**
Communicable Diseases Epidemiology Office,
Washington State Department of Health, Seattle, WA
Administered by Epidemiology Program Office, CDC, Atlanta, GA
- 1996 **CDC Epidemic Intelligence Service (EIS)**
Respiratory Diseases Branch,
Division of Bacterial and Mycotic Diseases,
National Center for Infectious Diseases, CDC, Atlanta, GA
- 1994 **Internal Medicine Residency**
Department of Medicine
University of Alabama at Birmingham School of Medicine,
Birmingham, AL

Graduate

- 1991 **Doctor of Medicine**
Baylor College of Medicine,
Houston, TX
Completed in combination with M.P.H. at UT SPH
- 1991 **Master of Public Health**
University of Texas School of Public Health,
Houston, TX
Completed in combination with M.D. at Baylor College of Medicine
Thesis: Epidemiologic Factors Associated with Antibiotic-Resistant
Urinary Tract Infections in Children.

Undergraduate

1986 **Bachelor of Science**
Duke University, Durham, NC
Major: Zoology, Secondary Emphasis: Philosophy

Professional Licenses and Certification

2015 American Board of Internal Medicine, Certification
1997 American Board of Preventive Medicine, Board Eligible
1994 American Board of Internal Medicine, Certification
1992 Alabama Medical License # 16840, status-active, expires 12-31-2024
1992 Texas Medical License # J1531, Issued 8/21/92, Status-Inactive

Professional Experience – Positions Held and Long-Term Temporary Assignments

February 1, 2023 – Present

Director, National Center for Emerging and Zoonotic Infectious Diseases
Distinguished Consultant, RF-0602 (Indefinite)
Centers for Disease Control and Prevention (CDC)
Atlanta, GA 30333

As Director of the National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), oversee a broad portfolio of activities for CDC, including around 1900 employees, over 2,000 contract and training staff, in eight divisions that work with partners throughout the United States and around the world to prevent illness, disability, and death caused by a wide range of infectious diseases. The annual appropriated base budget is approximately \$800M. Information on NCEZID is available at [National Center for Emerging and Zoonotic Infectious Diseases \(NCEZID\) | CDC](#). NCEZID is comprised of:

- Division of Foodborne, Waterborne, and Environmental Diseases (DFWED)
- Division of Infectious Disease Readiness and Innovation (DIDRI)
- Division of Core Laboratory Services and Response (DCLSR)
- Division of Healthcare Quality Promotion (DHQP)
- Division of Global Migration Health (DGMH)
- Division of High Consequence Pathogens and Pathology (DHCPP)
- Division of Vector-Borne Diseases (DVBD)
- Division of Parasitic Diseases and Malaria (DPDM)
- Office of Advanced Molecular Detection (OAMD)
- One Health Office (OHO)
- Health Equity Office (HEO)

NCEZID's accomplishments for 2022 are available at [NCEZID Accomplishments 2022 | What We Do | NCEZID | CDC](#), including:

- Advanced Molecular Detection support for genomic sequencing
- Antimicrobial resistance monitoring and intervention
- Emerging infectious diseases such as Ebola, Marburg, Nipah, and *Candida auris*
- Healthcare safety
- Quarantine stations and Traveler's Genomic Surveillance
- Mosquito mitigation technology
- Wastewater surveillance

- Mpox response and vaccination initiative
- Outbreaks of foodborne, waterborne, vector-borne, and other infectious threats

NCEZID's 2024 Center Priorities align with CDC's priorities and are grouped into three categories: infectious disease response readiness, program accountability, and equity.

Priority 1: Strengthening Infectious Disease Response Readiness

- NCEZID is working to ensure its readiness for responses to infectious threats through improvements in four main areas:
 - Operational response readiness,
 - Data systems response readiness,
 - Laboratory test readiness
 - Global response readiness.

Priority 2: Program Accountability

- NCEZID is working to raise accountability with an emphasis on measurable results. The center and each division have established at least four objectives, key results, and timelines related to its investment strategies.

Priority 3: Equity

- NCEZID is working to promote equity through:
 - Workforce efforts to achieve diversity, equity, inclusion, and accessibility,
 - Utilizing program work and funding mechanisms to achieve greater understanding of, and interventions for achieving, health equity.

August 1, 2021 – February 1, 2023

Deputy Director for Public Health Science and Surveillance

Distinguished Consultant, RF-0602 (Indefinite)
Centers for Disease Control and Prevention (CDC)
Atlanta, GA 30333

As Deputy Director for Public Health Science and Surveillance, served as one of four Deputy Directors to the CDC Director, responsible for:

- **Public Health Science and Surveillance Community of Practice** – Responsible for strengthening CDC's scientific and surveillance foundation by leading and overseeing work across four offices/centers: **National Center for Health Statistics, Office of Science; Office of Laboratory Science and Safety; and the Center for Surveillance, Epidemiology, and Laboratory Services** to:
 - Improve laboratory quality at CDC and with public health partners through implementation of new quality processes and requirements
 - Improve public health workforce at CDC and across State, Territorial, Local, and Tribal health departments
 - Expand policies and procedures throughout the CDC for statistics and health information technology transfers in intramural and extramural research and development
 - Provide leadership in the formulation and communication of CDC 's public health sciences centered on surveillance, epidemiology, statistics, laboratory services, informatics, through intramural and extramural research and development
 - Represent the CDC and DDPHSS with other departments, and national and international health officials including state, tribal, local and territorial health departments; other Federal, state, and local government agencies; industry and labor groups; academia; and others.
- **Data Modernization Initiative (DMI)** – Oversaw a broad \$1B+ portfolio of activities for transforming public health data systems to address critical gaps and improve collection, sharing, timeliness and utility of data at CDC and among partners at State, Territorial, Local

- and Tribal public health agencies. The goal is to move from siloed and brittle public health data systems to connected, resilient, adaptable, and sustainable systems that can help public health solve problems before they happen and reduce the harm caused by the problems that do happen. Efforts are focused on:
- Building and aligning CDC and public health partners to a foundational infrastructure for the future
 - Establishing a cloud-based environment for greater data integration and shared services
 - Implementing a hub and spoke approach for data sharing
 - Focusing data collection improvements on core program-agnostic systems
 - Planning and executing a transition of legacy systems to use foundational infrastructure
 - Accelerating data into action
 - Establishing a common access to various curated datasets
 - Implementing a common operating picture to support scalable outbreak responses
 - Developing and testing new standards in anticipation of national FHIR requirements
 - Incorporating predictive analytics to improve disease forecasting
 - Building a highly skilled public health workforce
 - Serving as Community of Practice lead over the Center for Surveillance, Epidemiology, and Laboratory Services administering a \$3B grant for >100 jurisdictions over 5 years to address critical public health workforce needs
 - Leveraging and expanding partnerships
 - Managing change and governance
- **Supporting Initiation of a New National Center for Epidemic Forecasting and Outbreak Analytics** – Through a \$200M effort in coordination with data modernization at CDC, supporting the CDC Director's vision to establish a new center to collect data; model and forecast public health concerns; and share information in real time to trigger governmental, private sector, and public actions to respond both within the U.S. and abroad. The center will advance the use of forecasting and outbreak analytics in public health decision making with the goal of supporting more efficient and effective outbreak response. It will accomplish this mission by bringing together next-generation public health data, expert infectious disease modelers, public health emergency responders, and high-quality communications to meet the needs of decision makers.
 - **Information Technology and Data Governance (ITDG)** – Served as Co-Chair for CDC's ITDG, a new governance approach and structure that supports enterprise-wide accountability for IT and data investments. ITDG is a critical requirement for implementing the Data Modernization Initiative.
 - **Leading HHS Efforts for Presidential Directives on Public Health Data** – Chaired HHS committees to respond to the Executive Order Ensuring a Data-Driven Response to COVID-19 and Future High-Consequence Public Health Threats. Efforts address improving public health data scientist workforce; open data access; the effectiveness, interoperability, and connectivity of public health data systems, and innovations in public health data and analytics.

June 1, 2015 – August 1, 2021

Director, Influenza Division

Distinguished Consultant, RF-0602 (Indefinite)

National Center for Immunization and Respiratory Diseases (NCIRD)

Centers for Disease Control and Prevention (CDC)

Atlanta, GA 30333

Served as Director for the Influenza Division. Responsible for supervision of staff and direction for:

- **Scientific and Strategic Oversight** – As Director, provided:
 - Vision, leadership and direction for the Influenza Division to improve detection, treatment, and prevention of seasonal, novel, and pandemic influenza, including:
 - Ongoing monitoring of seasonal and novel influenza viruses globally through epidemiologic and laboratory surveillance
 - Twice yearly selection of vaccine viruses for Northern and Southern Hemisphere vaccine manufacturing
 - Clinical guidance for antiviral treatment and virus monitoring for development of antiviral resistance
 - Regular influenza risk assessments of emerging novel influenza viruses causing disease in humans with development of pre-pandemic vaccine viruses
 - Support for external partnerships and crosscutting activities that support quality science and strong global partnerships.
 - Leadership and guidance in policy formulation.
 - Support for national and international capacity building programs.
 - Technical expertise and leadership for national and international pandemic preparedness and response activities.
 - Technical expertise for communications, information technology, genomic sequencing, and reagent resources.
- **Budget** – Directed the formulation and execution of annual budget, varying annually from approximately \$118-305M. Managed a complex set of funding sources and funding mechanisms for work in the U.S. and abroad. Established flexible, novel contract and grant mechanisms to allow for rapid surge in staff, resources, and services in emergencies, as utilized in 2009 Pandemic, 2013 H7N9 emergency responses, and 2020 COVID-19 response.
- **Policy and Planning** – Directed strategic planning and program monitoring and evaluation. Assure Division activities are flexible and able to align with strategic goals in a dynamic environment. Supervised staff responsible for all congressional, USG, OIG, GAO, FOIA and other inquiries and reports. Represent CDC, DHHS, and USG on various policy matters regarding vaccines, surveillance, antiviral treatment, and international capacity building. Required to explain and defend policies and decisions that may be controversial or in conflict with other agencies or partners.
- **Communications** – Supervised a team of communications professionals responsible for journalist inquiries, Division campaigns, crisis communications, and all influenza content on the CDC web and in CDC's social media. Served as a recognized internationally known scientific expert and spokesperson to professionals and the public about influenza and emerging infectious diseases.
- **Scientific Excellence** – Supervised staff responsible for assuring the Division's research reflects the highest scientific integrity and that the science and information is high quality, reliable, and objective. Provided a regular forum for discussions and presentations to maintain high-level scientific competence in the Division and for advancing the state of influenza scientific knowledge and inquiry. Assured laboratory quality, biosafety, and biosecurity are optimally executed and adherent to all regulations.
- **Administration, Management, and Scientific Operations** – Supervised staff responsible for Division procurement, accountability, personnel (approximately 300 employees and contractors), equipment, and facilities. Supervised staff managing a broad international portfolio for epidemiologic and laboratory capacity building, pandemic preparedness, and international influenza surveillance. Developed and manage staff executing the International Reagent Resource, a 10 year, award-winning, \$100M contract for routine and emergency distribution of diagnostic kits, reference viruses, antibodies, proteins, and other influenza reagents for use at over 100 National Influenza Centers globally, over 60 public health labs in

- the U.S., and for researchers and manufacturers of new influenza vaccines, therapies, and diagnostics.
- **Pandemic Preparedness and Response** – Supervised staff responsible for Division-wide epidemiologic and laboratory preparedness planning and exercising. Developed, evaluated, and implemented novel approaches for national pandemic responses and risk assessment, including “Intervals, Triggers, and Actions” which now serves as the federal organizational framework for pandemic influenza response, and the “Pandemic Severity Framework” for use in assessing the impact of an emerging pandemic. In the event of an influenza pandemic, will serve as CDC Incident Commander for USG pandemic response. Served as Incident Manager of CDC Ebola Response in 2015. Served as Incident Manager for 2020 COVID-19 response. Maintained highest level of appropriate clearance for national security. Represents CDC on SVTC novel and seasonal influenza planning and response meetings with National Security Council staff.
 - **Information Resources and Science** - Responsible for Division’s broad portfolio of bioinformatics, next-generation sequencing, genomic epidemiology, virus fitness forecasting, electronic laboratory reporting using standard messaging, syndromic surveillance, infectious diseases modeling and predictive analytics, machine learning of structured and unstructured data, cloud computing, cloud-based sequencing and laboratory reporting, federated data lakes for epidemiologic and laboratory data integration, and other information resources and applications.

June 16, 2006 – May 30, 2015

Deputy Director, Influenza Division

National Center for Immunization and Respiratory Diseases (NCIRD)
Centers for Disease Control and Prevention (CDC)
Atlanta, GA 30333

- Served as Deputy Director, Senior Medical Officer, and Senior Public Health Service Officer for the Influenza Division. Responsible for supervision of staff and direction for budget, policy and planning, communications, scientific excellence, administration, management, and scientific operations, and pandemic preparedness and response.
- Supervised eight direct reports, including medical officers, microbiologists, public health analysts and advisors, policy staff, and administrative personnel. These staff members were employed through the civil service (up to GS-14), Commissioned Corps (up to O-6), and Title 42 Fellowship (up to GS-14 equivalent).
- Formulated, developed, implemented, and evaluated international and domestic influenza surveillance, epidemiologic research, prevention, and treatment activities.
- Maintained highest levels of clearance appropriate for engaging in matters of national security.
- Served in temporary assignments at the request of Agency leadership to address emerging issues.

November 26, 2012 – September 1, 2013 (Temporary Assignment by Request from CDC Director)

Acting Deputy Director,

Office of Surveillance, Epidemiology, and Laboratory Services (OSELS),

CDC, Atlanta, GA

- Detail requested by CDC Director for reorganization and right-sizing of OSELS
- Developed and implemented a four-phase organizational improvement and restructuring plan for OSELS accounting for 471 full-time employees, 413 contractors, and 197 full-time employees in training fellowships, with an annual budget of \$212 M.
- At completion, consolidated four separate Program Offices into one new Center, consolidated ten Divisions to four, and consolidated twenty-four Branches to thirteen.
- Established and executed strategic objectives for improving surveillance integration, public

health workforce training, tools for epidemiologic analysis, and laboratory efficiency and coordination.

September 1, 2005 – March 1, 2006

**Associate Director for Epidemiologic Science,
Division of Healthcare Quality Promotion (DHQP),
National Center for Infectious Diseases (NCID),
CDC, Atlanta, GA**

- Provided medical and epidemiologic subject matter expertise for the Division and Center. Responsible for Division's scientific agenda, integrity, and compliance with all regulatory and human subject protection requirements
- Represented the Division, Center, and Agency on various committees and partnerships regarding patient safety, public reporting of healthcare-associated infections, healthcare information technology, scientific quality, and emerging infectious disease responses.
- Provided leadership and established goals, objectives, and priorities for the Division's epidemiologic, investigative, response, and surveillance activities in healthcare settings.

March 1, 2005 – August 31, 2005 (Temporary Assignment by Request from NCID OD)

**Associate Director for Epidemiologic Science,
National Center for Infectious Diseases,
CDC, Atlanta, GA**

- Detail requested by NCID Director during restructuring of CDC's infectious diseases activities.
- Assured and fostered the quality and clear communication of scientific information for the Center. Reviewed major scientific reports and publications for the Center, and oversaw institutional review board and human subjects approval processes for the Center. Supervised staff responsible for maintaining and applying for regulatory approval for vaccines and drugs for use in response to bioterrorism.
- Served as HHS lead for external peer review of the DHHS Secretary's Pandemic Influenza Strategic Plan, and led Center-level infectious disease emergency responses, including investigation to identify the root cause of laboratory errors leading to inadvertent release of H2N2 influenza virus, a pandemic strain that has not been in circulation since 1968.

July 13, 2001 – February 28, 2005

**Chief, Epidemiology Section,
Division of Healthcare Quality Promotion,
National Center for Infectious Diseases,
CDC, Atlanta, GA**

- Directed, coordinated, and exercised a full range of supervisory, management, and subject matter duties over an office of nine epidemiologists and support staff serving as CDC's rapid response resource for healthcare-associated infections issues.
- Planned, directed, and published numerous investigations and studies of healthcare-associated and device-associated infections, notably organ and tissue transplant-associated infections and deaths, leading to significant changes in national policies and regulations.

July 6, 1999 – July 12, 2001

**Senior Medical Officer, Office of Surveillance,
National Center for Infectious Diseases,
CDC, Atlanta, GA**

- Supported various aspects of CDC's Emerging Infections activities. Served as CDC liaison to

- the Infectious Disease Society of America Emerging Infections Network.
- Implemented various projects for improving surveillance for emerging infections and for integrating surveillance activities. Defined and implemented the electronic messaging specification for automated reporting of public health laboratory findings using national standards for healthcare electronic communications. This approach was adopted in 2011 as part of the Medicare and Medicaid Programs' Electronic Health Records Incentive Program.

July 1, 1997 – July 5, 1999

Medical Epidemiologist, Office of Surveillance

National Center for Infectious Diseases, CDC, assigned to:
Communicable Diseases Section, Washington State Department of Health,
Seattle, WA

- Performed and supervised outbreak investigations and provided consultation on disease control issues. Participated in revision of communicable diseases regulations for Washington State.
- Implemented automated electronic reporting of public health findings from a large health maintenance organization to the Washington State Department of Health.
- Developed and implemented a statewide judicious antimicrobial use campaign in Washington State.

Clinical and Academic Duties

2009 – Present

Lecturer
Department of Epidemiology and Department of Medicine
Rollins School of Public Health and School of Medicine
Emory University
Atlanta, GA

2017 – 2019

PhD Thesis Committee Member
Department of Epidemiology
School of Public Health and Tropical Medicine
Tulane University
New Orleans, LA

1997 – 2008

Physician (Locum tenens two weeks per year)
Neah Bay Service Unit, Indian Health Service
Makah Indian Reservation
Neah Bay, WA

1996 – 2004

Clinical Assistant Professor (Lecturer and MPH Thesis Advisor)
Department of Epidemiology
School of Public Health and Community Medicine
University of Washington
Seattle, WA

Special Assignments, Deployments, and Emergency Responses

Mar 20 – June 13, 2020

CDC Lead Official, Federal Emergency Management Agency (FEMA) and Department of Health and Human Services (DHHS) Joint Response to Coronavirus Disease 2019 (COVID-19);

FEMA National Response Coordination Center (NRCC), Washington DC

- Served as CDC Lead Official to the FEMA-HHS Unified Coordination Group (UCG). The UCG functioned as a multiagency coordination entity and worked to establish joint priorities and allocate resources (personal protective equipment, ventilators, diagnostics, pharmaceuticals, and others), resolve agency policy issues, and provide strategic guidance to support the Federal COVID-19 response.
- Served as primary representative from CDC's Incident Management System to the Federal Incident Management System
- Supervised team of CDC staff deployed to the NRCC varying in size from 12 to 26, in support of NRCC Task Forces:
 - Community Mitigation Task Force
 - Healthcare Resilience Task Force
 - Supply Chain Task Force
 - Laboratory Diagnostics Task Force
 - Data Analysis Task Force
 - Communications
 - Policy
- During service as Incident Manager and NRCC Lead from January to June, 2020, CDC responded with the following:
 - 5,505 CDC personnel supporting the outbreak response
 - 306,000+ arriving international passengers screened at US airports
 - 1,797 documents providing information and guidance for government agencies, businesses, and the public
 - 277,000+ calls and emails to CDC-INFO
 - 1.7+ billion social media impressions on 3,655 CDC response-related posts
 - 1,037 CDC deployers had conducted 1,472 deployments to 116 cities across the United States and abroad
 - 22+ million COVID-19 tests conducted by public and private laboratories
 - 25+ million times people had used CDC's online self-checking tool, "Clara"
 - 23,000+ inquiries to CDC from doctors, nurses or other clinical staff and health departments
 - 1.4 billion times people had viewed information on CDC websites

Jan 19 – Mar 20, 2020

Incident Manager, CDC Global Response to Coronavirus Disease 2019 (COVID-19)

Emergency Operations Center, CDC, Atlanta, GA

- Served as Incident Manager of CDC's overall global response to COVID-19
- Managed approximately 800 CDC staff to mitigate the emergence of COVID-19 through CDC Task Forces to address:
 - Epidemiology and surveillance
 - Modeling and forecasting
 - Data and analysis
 - Laboratory testing
 - Community mitigation
 - Medical countermeasures
 - Infection control
 - Worker safety
 - At-risk individuals

- International outbreak response
- Global migration and Quarantine
- Animal-associated infections
- State, territorial, tribal engagement
- See the following reports:
 - Jernigan DB; CDC COVID-19 Response Team. Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 28;69(8):216-219.
 - Patel A, Jernigan DB; 2019-nCoV CDC Response Team. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 7;69(5):140-146.

Mar 2015 – Aug 2015

Incident Manager, CDC Global Ebola Response, Emergency Operations Center, CDC, Atlanta, GA

- Deployment requested by CDC Director to supervise all operations and staff in the U.S., Liberia, Sierra Leone, and Guinea responding to the ongoing epidemic of Ebola in West Africa
- Oversaw >250 deployed staff to West Africa and >300 staff in Atlanta Emergency Operations Center.
- Developed and executed response budget of \$325M.
- See: Bell BP, Damon IK, Jernigan DB et al. Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014-2016 Ebola Epidemic. MMWR Suppl. 2016 Jul 8;65(3):4-11.

Dec 2014 – Jan 2015

Lead, Sierra Leone Ebola Response Team, CDC Sierra Leone Country Office, Freetown, Sierra Leone

- Supervised Ebola response activities including epidemiology, surveillance, laboratory, contact tracing, safe burials, case management, communications, and social mobilization
- Executed “Western Area Surge” initiative to improve case identification and contact monitoring, averaging around 70 – 100 confirmed Ebola cases per day.
- See: Durski KN, Naidoo D, Singaravelu S, Shah AA, Djingarey MH, Formenty P, Ihekweazu C, Banjura J, Kebela B, Yinka-Ogunleye A, Fall IS, Eteng W, Vandi M, Keimbe C, Abubakar A, Mohammed A, Williams DE, Lamunu M, Briand S, Changa Changa JC, Minkoulou E, Jernigan D, Lubambo D, Khalakdina A, Mamadu I, Talisuna A, Mbule Kadiobo A, Jambai A, Aylward B, Osterholm M. Systems thinking for health emergencies: use of process mapping during outbreak response. BMJ Glob Health. 2020 Oct;5(10):e003901. doi: 10.1136/bmjgh-2020-003901

June 2013

Temporary Advisor, World Health Organization, Mission Concerning the Middle East Respiratory Syndrome – Coronavirus (MERS-CoV) Riyadh, Kingdom of Saudi Arabia,

- Served as epidemiologist for WHO team investigating rapid increase in MERS-CoV cases
- See: Williams et al. CDC's Early Response to a Novel Viral Disease, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), September 2012-May 2014. Public Health Rep. 2015 Jul-Aug;130(4):307-17.

April – May 2013

Lead, Avian Influenza H7N9 Epidemiology and Laboratory Task Force,

CDC Emergency Response to Human Cases of Avian Influenza A(H7N9) in China,
Emergency Operations Center, CDC, Atlanta, GA

- Supervised staff of around 70 people responding to emergence of novel influenza in China
- See: Jernigan DB et al. H7N9: preparing for the unexpected in influenza. *Annu Rev Med.* 2015;66:361-71.

September 2012 – April 2013

Deputy Lead, Global Health Security Agenda Development Team

Office of the Director, CDC, Atlanta, GA

- Requested by CDC Director to support development of a USG Global Health Security Agenda strategy
- Developed proposal for a five-year \$1.5 B budget plan. Effort later informed budget planning of CDC supplemental funds for Ebola and GHSA in 2014.

April 2009 - June 2010

Lead, Pandemic Influenza H1N1 Epidemiology and Laboratory Task Force,

U.S. Federal Response to 2009 H1N1 Influenza Pandemic,
Emergency Operations Center, CDC, Atlanta, GA

- Task Force reached a peak census of 487 members (including a majority of Influenza Division staff), and was responsible for outbreak response, epidemiology, surveillance, laboratory, international, modeling, pediatric and vulnerable populations, animal-human interface, and other issues. Direct budget for the Task Force was \$149 M
- Task Force findings were summarized in 29 publications in the January 2011 volume of *Clinical Infectious Diseases* (http://cid.oxfordjournals.org/content/52/suppl_1.toc) and in other journals including *NEJM*, *Science*, *EID*, and *MMWR*.

September - November 2005

Lead, PHS Deployment to San Antonio Hurricane Katrina Response Team,

Incident Command Post, San Antonio, TX, and

Team Lead for Atlanta-based Outbreak Response and Clinical Team

Emergency Operations Center, CDC, Atlanta, GA

- Supervised team to establish a “Health Department in a Box” to serve 13,000 evacuees; characterized and published various infectious diseases issues affecting evacuees
- See:
 - Jhung et al. Chronic disease and disasters medication demands of Hurricane Katrina evacuees. *Am J Prev Med.* 2007 Sep;33(3):207-10.
 - CDC. Infectious disease and dermatologic conditions in evacuees and rescue workers after Hurricane Katrina--multiple states, August-September, 2005. *Sep 30;54(38):961-4.*
 - CDC. Vibrio Illnesses After Hurricane Katrina --- Multiple States, August--September 2005. *MMWR Sep 23;54(37):928-31.*
 - CDC. Morbidity Surveillance After Hurricane Katrina --- Arkansas, Louisiana, Mississippi, and Texas, September 2005. *MMWR 2006;55(26);727-731*

March – July 2003

Lead, CDC/WHO SARS Investigation Team,

Taipei and Kaohsiung, Taiwan, and

Co-Lead, Clinical and Infection Control Team

Emergency Operations Center,

CDC, Atlanta, GA

- Supervised CDC and WHO staff investigating hospital and community cases of SARS

- during peak of epidemic
- See:
 - McDonald LC et al. SARS in Healthcare Facilities, Toronto and Taiwan. *Emerg Infect Dis* 2004 May; 10(5):777-781.
 - Srinivasan A et al. Foundations of the severe acute respiratory syndrome preparedness and response plan for healthcare facilities. *Infect Control Hosp Epidemiol.* 2004;25(12):1020-5.
 - Braden C et al. Progress in Global Surveillance and Response Capacity 10 Years after Severe Acute Respiratory Syndrome. *Emerg Infect Dis.* 2013 June; 19(6): 864–869.

August – November 2002

Lead, West Nile Virus in Organ Recipients Team,
National West Nile Virus Response,
Emergency Operations Center,
CDC, Atlanta, GA

- Supervised investigative team revealing West Nile Virus as a bloodborne pathogen capable of infecting blood supply and causing organ transplant-associated illness.
- See: Iwamoto et al. Transmission of West Nile virus from an organ donor to four transplant recipients. *N Engl J Med.* 2003 May 29;348(22):2196-203.

October – December 2001

Lead, Atlanta-based Anthrax Epidemiology and Surveillance Team,
National Response to Bioterrorism-Related Anthrax
Emergency Operations Center,
CDC, Atlanta, GA

- Supervised CDC Headquarters team responsible for coordination of epidemiology and surveillance
- Responsible for coordinating all MMWR publications of the response
- See: Jernigan D, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. *Emerg Infect Dis.* 2002 Oct;8(10):1019-28.

Public Health Service (PHS) Awards and Honors Occurring Prior to PHS Retirement in 2019

2017	Global Response Service Award given in recognition of the officer's substantial contribution to the international Ebola response.
2017	Ebola Campaign Medal given for support of the international Ebola response.
2016	Outstanding Unit Citation given for outstanding leadership, unwavering dedication, and personal sacrifices which saved countless lives and prevented a global catastrophe during the Ebola outbreak.
2016	Outstanding Unit Citation given for exemplary public health support during the humanitarian emergency response during the surge of unaccompanied children crossing the Southwest US border.
2016	Presidential Unit Citation given for extraordinary courage and the highest level of performance in action throughout the United States Government's response to the Ebola outbreak in West Africa.
2014	Outstanding Unit Citation given to the Global Health Security Demonstration Project Team in recognition of multidisciplinary leadership and coordination of the CDC Director's priority initiative to build global health security capacity in Uganda and Vietnam.
2014	Outstanding Unit Citation given to the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) team in recognition of excellence in responding to and mitigating the potential public health consequences related to a novel coronavirus.
2013	Unit Commendation given to the Zoonotic Disease Education Team in recognition of

- exemplary teamwork and dedication to the public and scientific excellence for efforts to prevent novel influenza and zoonotic diseases.
- 2013 **Outstanding Unit Citation** given to the Variant Influenza Outbreak Investigation Team for exemplary teamwork, dedication to the public and scientific excellence in the response to variant influenza A infections with pandemic potential in the US.
- 2013 **Unit Commendation** to the Interagency Rapid Influenza Diagnostics Improvement Team for exceptional work in improving the performance of commercially available rapid assays for the detection and diagnosis of influenza.
- 2012 **Outstanding Unit Citation** to the HHS Interagency Seasonal Influenza Task Force (ISITF) for outstanding coordination of systemic public health interventions across the U.S. Government in implementing the first universal recommendation for influenza vaccination for all Americans over the age of six months.
- 2010 **Special Assignment Award** to the Tier I and Tier II PHS Response Teams (2006-2009) in recognition of three years participation.
- 2010 **Distinguished Service Medal** (individual award and the highest decoration of the PHS) in recognition of outstanding individual contribution to improving global influenza detection and response through innovations in diagnostic testing used before and during the 2009 H1N1 influenza pandemic.
- 2010 **Outstanding Unit Citation** to the H1N1 Task Force in recognition of leading the Department of Health and Human Services' prolonged response to the 2009 H1N1 influenza pandemic.
- 2010 **Unit Commendation** to the Flu Panel Team in recognition of exceptional performance and dedication in addressing complex regulatory and scientific issues with H1N1 testing.
- 2010 **Outstanding Unit Citation** to the CDC H1N1 Response Staff in recognition of CDC's early and effective response to Pandemic H1N1 (2009).
- 2008 **Unit Commendation** to the Biothreat and Chemical Threat Detection Team for contributions in the development of testing guidelines for use with emerging infectious diseases.
- 2008 **Outstanding Unit Citation** to the Clostridia Toxic Shock Syndrome Investigation Team for protecting public health through multi-agency investigation and response to cases of *Clostridium sordellii* and *perfringens*.
- 2007 **Outstanding Unit Citation** to the Pandemic Influenza Community Mitigation Strategy Team for furthering pandemic influenza preparedness and response efforts through publication of public health guidance.
- 2007 **Outstanding Unit Citation** to the Gulf Hurricanes Response Team 2005 for protecting public health of citizens of Louisiana, Texas, Florida and Mississippi after Hurricanes Katrina, Rita, and Wilma.
- 2006 **Outstanding Unit Citation** to the Marburg Response Team for outstanding teamwork, rapid response, and scientific excellence in public health response to the outbreak of Marburg virus hemorrhagic fever in Angola.
- 2006 **Achievement Medal** (Individual Honor) for outstanding individual contribution in use of root cause analysis to determine the source of laboratory errors allowing global distribution of a non-circulating H2N2 pandemic influenza strain for proficiency testing.
- 2006 **Crisis Response Service Award** for outstanding response to disaster management following Hurricane Katrina in Texas and Louisiana
- 2005 **Outstanding Unit Citation** to the Severe Acute Respiratory Syndrome (SARS) Preparedness Team in recognition of exemplary teamwork, dedication, and scientific excellence in enhancing the nation's preparedness for a recurrence of SARS.
- 2005 **Outstanding Unit Citation** to the West Nile Virus Surveillance and Response Team in recognition of response to the 2002 West Nile virus outbreak in the United States.
- 2005 **Regular Corps Ribbon** for assimilation into the USPHS Regular Corps.
- 2005 **Commendation Medal** (Individual Honor) for outstanding individual contribution to national electronic health information standards, public health informatics, and communicable diseases surveillance.

- 2005 **Outstanding Unit Citation** to the Monkeypox Response Team for outstanding teamwork, rapid response, and scientific excellence during public health response to an outbreak of monkeypox in the United States.
- 2005 **Outstanding Unit Citation** to the Severe Acute Respiratory Syndrome (SARS) Response Team for exemplary teamwork and scientific excellence in the investigation and control of SARS during the acute public health response.
- 2004 **Unit Commendation Award** to the Cochlear Implant and Meningitis Investigation Team for identifying the association between cochlear implants and meningitis and carrying out an effective public health response.
- 2004 **Unit Commendation Award** to the CDC Vancomycin-resistant *Staphylococcus aureus* Team for rapid response and exemplary teamwork investigating and controlling spread of the first two confirmed infections caused by vancomycin-resistant *Staphylococcus aureus*.
- 2003 **Unit Commendation Award** to the Tissue Safety Enforcement Group contributions in protecting public health via collaborative effort with the CDC and FDA regarding human tissue for transplantation.
- 2003 **Achievement Medal** (Individual Honor) for individual contribution in surveillance for emerging infectious diseases through work with the Emerging Infections Network of the Infectious Diseases Society of America.
- 2002 **Outstanding Unit Citation** to the DHHS Terrorist Response Team for outstanding service to the people of the United States in responding to terrorist attacks.
- 2002 **Crisis Response Service Award** to the 'Response to the Anthrax Attacks on the United States' for participation in national response to bioterrorism-related anthrax attacks on the United States.
- 2000 **Unit Commendation Award** to the World Trade Organization Enhanced Surveillance Project Team for contributions in conducting surveillance for bioterrorism associated with the World Trade Organization, Seattle, WA.
- 1998 **Bicentennial Unit Commendation** for extended active duty service during the Public Health Service's 1998 bicentennial year.
- 1998 **Unit Commendation Award** to the Electronic Laboratory-Based Reporting Team for contributions to enhance public health surveillance through electronic laboratory-based reporting of emerging infectious diseases.

Awards and Honors, Non-Public Health Service

- 2023 **Changemaker in Health Award**, Winner for Policy Influencer, Healthcare Information Management Systems Society (HIMSS)
- 2019 **Service to America Medal**: Winner of the Samuel J. Heyman Service to America Medal (Sammie) in Science and Environment for "Led response efforts for dozens of disease crises, including Ebola, SARS, and West Nile virus, while greatly improving our country's ability to identify, prepare for and respond to inevitable flu pandemics".
<https://servicetoamericamedals.org/honorees/daniel-b-jernigan-m-d/>.
- 2018 **Food and Drug Administration Outstanding Service Award**: Reclassification of rapid influenza virus antigen detection test systems (RIDT) from class I to class II with special controls.
- 2018 **CDC and ATSDR Honor Award: Excellence in Partnering – International**, for excellence in leading the U.S. government response to a large increase in avian influenza A/H7N9 infections in humans
- 2018 **NCIRD Certificate of Excellence** for dedication to enhancing the efficiency of the nation's public health system for influenza virus surveillance
- 2018 **NCIRD Certificate of Excellence** for excellence in leading the U.S. government response to a large increase in avian influenza A(H7N9) infections
- 2017 **NCIRD Certificate of Excellence** for exemplary leadership in transferring advanced

- molecular detection technology to domestic health surveillance partners.
- 2015 **CDC Certificate of Appreciation** for selfless contributions and willingness to go above and beyond the call of duty in response to the Ebola outbreak in West Africa
- 2015 **CDC and ATSDR Honor Award: Excellence in Partnering – Domestic** for partnering to create legislation for improved performance of influenza diagnostic assays.
- 2015 **CDC and ATSDR Honor Award: Excellence in Frontline Public Health Service** for superlative public health support during the humanitarian response to unaccompanied children crossing the U.S. border.
- 2014 **CDC Director’s Award for Efficiency** to the Influenza Diagnostics and Distribution Team for excellence in demonstrating performance of a new diagnostic reagent, encouraging cost competition, and saving funds.
- 2014 **CDC Center for Global Health Director’s Special Award for Strengthening Global Health Security** for excellence in international program delivery to strengthen global health security capacity in Uganda and Vietnam
- 2013 **CDC Certificate of Excellence** for improving our understanding of MERS-CoV epidemiology and fostering positive relationships with affected countries.
- 2011 **CDC Honor Award Nominee for Emergency Response—Domestic** for outstanding public health action in response to the emergence of an influenza virus with pandemic potential.
- 2010 **Presidential Award from the Association of Public Health Laboratories** for Extraordinary Support to Public Health Laboratories during the 2009 H1N1 Response.
- 2008 **Food and Drug Administration - Leveraging Collaboration Award** to the Biothreat and Chemical Threat Detection Team for exceptional collaborative interaction in addressing agency-wide issues associated with tests for novel emerging infectious diseases and for detecting biothreat and chemical threat agents.
- 2007 **Nakano Award** and **CDC Shepard Science Award Candidate Certificate** for outstanding peer-reviewed publication for 2006 entitled “Transmission of Lymphocytic Choriomeningitis Virus by Organ Transplantation” published in New England Journal of Medicine 2006;354:2235-2249.
- 2006 **Nakano Award** and **CDC Shepard Science Award Candidate Certificate** for outstanding peer-reviewed publication for 2004 entitled “Transmission of rabies virus from an organ donor to four transplant recipients” published in New England Journal of Medicine 2005;352:1103-11.
- 2005 **Texas Department of State Health Services Commissioner’s Recognition** for outstanding service to public health colleagues at state, regional, and local levels with great flexibility, skill and an exemplary level of collaborative spirit which enabled Texas to effectively respond to the unprecedented influx of evacuees affected by Hurricanes Katrina and Rita.
- 2005 **Nakano Award** and **CDC Shepard Science Award Candidate Certificate** for outstanding peer-reviewed publication for 2004 entitled “*Clostridium* infections associated with musculoskeletal-tissue allografts” published in New England Journal of Medicine 2004;350(25):2564-71.
- 2005 **CDC Director’s Certificate of Appreciation** for outstanding teamwork, rapid response, and scientific excellence in the public health response to an outbreak of Marburg in Angola.
- 2005 **Health Equity Honor Award**, National Center for Infectious Diseases, for contributions to minority health programs, research, and surveillance through prevention and control of infectious diseases among Native Hawaiians’ and Pacific Islanders.
- 2005 **Silo Busters Honor Award**, National Center for Infectious Diseases, for collaborative success in working with agency, federal, state, and other public health partners.
- 2005 **Recognition Award** from the Health Level Seven National Standards Development Organization for tremendous contributions to the organization and for serving on the Board of Directors for two years from 2003 through 2004.
- 2004 **Alexander Langmuir Award** for best epidemiologic study prepared for publication at

- 2004 CDC in 2004 for "Transmission of West Nile virus from an organ donor to four transplant recipients" published in *New England Journal of Medicine* 2003;348(22):2196-203.
- 2004 **Nakano Award** and **CDC Shepard Science Award Candidate Certificate** for outstanding peer-reviewed publication for 2003 entitled "Transmission of West Nile virus from an organ donor to four transplant recipients" published in *New England Journal of Medicine* 2003;348(22):2196-203.
- 2004 **Certificate of Completion**, Commissioned Officer Training Academy, United States Public Health Service, for Basic Officer Training Course.
- 2003 **Taiwan Department of Health Award** for contribution towards the containment of the Severe Acute Respiratory Syndrome outbreak in Taiwan.
- 2003 **Governor's Recognition 'Honorary Texan'**, commissioned by Governor Rick Perry in recognition for service to the State of Texas for preparedness and response to emerging infectious diseases.
- 2003 **Senate of the State of Texas Recognition** awarded by Senator Gonzalo Barrientos for service to the State of Texas in sharing public health knowledge.
- 2003 **Nakano Award** and **CDC Shepard Science Award Candidate Certificate** for outstanding peer-reviewed publication for 2002 entitled "Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings" published in *Emerging Infectious Diseases* 2002;8:1019-28.
- 2002 **Certificate of Appreciation**, Federal Emergency Management Agency, in grateful appreciation for professionalism, compassion and courage in supporting the people of New York affected by the September 11, 2001 World Trade Center attack.
- 2002 **CDC Director's Recognition** for extraordinary efforts on behalf of the American people in response to the public health emergencies after September 11, 2001.
- 2000 **CDC Office of the Director's Recognition** for contributions to surveillance integration.
- 2000 **CDC & ATSDR Group Honor Award** for Service to the Public as part of the World Trade Organization Enhanced Surveillance Project Team.
- 1998 **Food and Drug Administration Recognition Award** for Unpasteurized Odwalla® Apple Juice and the *E. coli* Outbreak Response Team, FDA, DHHS.
- 1998 **State Secretary of Health Recognition Award**, Washington State Department of Health, for Surveillance for Antimicrobial Resistant *Streptococcus pneumoniae*.
- 1995 **Donald C. Maeckle Award**, CDC, for "Use of urinary antigen testing to detect an outbreak of nosocomial Legionnaires' disease. Lepine L, Jernigan DB, Wyatt B, et al."
- 1992 **Frank Cobbs Intern Award**, University of Alabama, Birmingham, AL
- 1989 **Public Health Service Traineeship Award**, UT School of Public Health, Houston, TX
- 1988 **Frank Netter Award**, Baylor College of Medicine, Houston, TX
- 1986 **Cum laude**, Duke University, Durham, NC

Committee Service

- 2023-Current **International Pathogen Surveillance Network**, founding member, World Health Organization
- 2023-Current **NIH Advisory Council** for the National Institute for Allergy and Infectious Diseases (NIAID)
- 2022-Current **Scientific and Technical Advisory Group for Infectious Hazards (STAG-IH)**, Co-Vice Chair, World Health Organization
- 2022-2024 **National Academy of Medicine Leadership Consortium**, member
- 2021-2022 **HHS Executive Order Committees**, Chair/Co-Chair of three committees to respond to the Executive Order Ensuring a Data-Driven Response to COVID-19 and Future High-Consequence Public Health Threats
- 2020-2022 **SARS-CoV-2 Interagency Group (SIG)**, Co-Chair, overseeing coordination of NIH, BARDA, CDC, DoD, DHS, and USDA engagements for risk assessment of variant SARS-CoV-2 virus surveillance and impact on countermeasures.

- 2020-2022 **National Academy of Medicine, International Committee on Advancing Pandemic and Seasonal Influenza Vaccine Preparedness and Response**, Committee Member
- 2020-2023 **Data Modernization Initiative**. National Center for Immunization and Respiratory Diseases Implementation Lead for CDC activity to modernize surveillance and information science and resources.
- 2019-2022 **National Influenza Vaccine Manufacturing Strategy Workgroup**. CDC member of Executive Office of the President National Security Council-DoD-HHS group implementing a multi-year strategy for improving influenza vaccine.
- 2019-2023 **Information Technology and Data Governance Committee**. Co-Chair. Prior to Feb 2021, member of CDC committee responsible for Data Modernization Initiative implementation. Lead for strategy development of \$143 M plan for surveillance system modernization.
- 2018-2021 **Potential Pandemic Pathogens Care and Oversight Group (P3CO)**, Member of HHS committee responsible for governance of federal funding for dual use laboratory research of concern
- 2018-2021 **Joint Department of Defense – Centers for Disease Control and Prevention Coordination Committee**, NCIRD Representative
- 2018-2022 **Options X for the Control of Influenza**, International Society for Influenza and Other Respiratory Virus Diseases, Organizing Committee Member
- 2017-2022 **Interagency Influenza Risk Management Committee (FRMM)**, Co-Chair overseeing influenza preparedness and response countermeasure development and prioritization in USG (HHS, BARDA, NIH, FDA, DOD, DHS, USDA, CDC)
- 2017-2019 **Novel Influenza Strategy and Response Planning**, Executive Office of the President National Security Council Interagency Sync Committee
- 2017-2018 **International Meeting on Respiratory Pathogens, Singapore**, Planning Committee Member.
- 2017-2021 **Disaster Leadership Group (DLG)**, Member representing CDC for coordination at HHS for influenza-related issues
- 2016-2019 **FDA Microbiology Devices Panel**, CDC Representative
- 2016-2017 **WHO Influenza Research Agenda Technical Working Group**
- 2014-2021 **WHO Vaccine Consultation on the Composition of Influenza Virus Vaccines**, CDC Collaborating Center Biannual Participant, Geneva, Switzerland
- 2014-2017 **Immunization Strategy Steering Committee**, NCIRD/CDC, Member
- 2014-2016 **Options IX for the Control of Influenza**, International Society for Influenza and Other Respiratory Virus Diseases, Organizing Committee Member
- 2013-2019 **Advanced Molecular Detection Steering Committee**, Member, NCIRD Co-Lead, CDC.
- 2013-2018 **Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Diagnostics Integrated Program Team**, HHS, Member for CDC.
- 2013-2015 **International Meeting on Respiratory Pathogens**, Planning Committee Member.
- 2013-2014 **International Classification of Diseases 9th to 10th Revision Transition Working Group**, Chair and CDC Federal Steward, CDC and DHHS.
- 2012-2014 **Global Health Security Implementation Task Force**, Member and Workgroup Chair, CDC and Interagency.
- 2011-2016 **Rightsizing Influenza Virologic Surveillance Working Group**, Co-Lead, CDC and Association of Public Health Laboratories.
- 2011-2012 **National Biosurveillance Strategy Working Group**, Member, National Security Staff, White House Sub-Interagency Policy Coordination Committee for Biosurveillance
- 2010-2021 **Improving Influenza Vaccine Virus Selection**, WHO Consultation, Participant
- 2010-2011 **Electronic Laboratory Reporting Task Force**, Team Lead, CDC and Council of State and Territorial Epidemiologists
- 2008-2014 **Public Health Laboratory Improvement Program Steering Group**, Advisor, Association of Public Health Laboratories
- 2007-2015 **Interagency Influenza Diagnostic Working Group**, Co-Lead, U.S. Government
- 2007-2018 **Emerging Infections Program Steering Group**, Member, CDC

2007-2009 **Biosurveillance Advisory Team**, Member, CDC
2006-2007 **Armed Forces Epidemiology Board**, CDC Representative
2005-2007 **National Pandemic Influenza Preparedness Plan Development Task Group**, Member and Coordinator of external peer reviewer, CDC
2005-2007 **Quality of Scientific Evidence Working Group**, Member, CDC
2004-2006 **Community-Associated Methicillin-Resistant *Staphylococcus aureus* Working Group**, Member, CDC
2004-2007 **Blood, Organ, and Other Tissue Safety Working Group**, Member, CDC
2000-2006 **Antimicrobial Resistance Working Group**, Member, NCID, CDC
2005 **Excellence in Science Committee**, Member, CDC
2003-2004 **National Severe Acute Respiratory Syndrome Preparedness Plan Development Task Group**, Member and Contributing Author, CDC
2003-2005 **Board of Directors**, Health Level Seven Standards Development Organization, Member
2003-2004 **Organ Transplant Advisory Committee**, Sub-Committee Member, DHHS
2002-2004 **Tissue Allograft Standards Committee**, Member, American Assoc of Tissue Banks
2001-2004 **Government Projects Special Interest Group**, Co-Chair and CDC Representative, Health Level Seven Standards Development Organization
2000-2002 **National Electronic Disease Surveillance System Operational Working Group**, Member, CDC Information Council
2000-2001 **Public Health Conceptual Data Model Task Group**, Member, CDC
2000-2003 **Information Modeling Committee**, CDC Representative, Health Level Seven Standards Development Organization
2000 **Notifiable Conditions Codes Working Group**, Co-Chair, Health Information Systems and Surveillance Board (HISSB), CDC
2000-2001 **Core Demographic Data Working Group**, Co-Chair, CDC
2000 **Group A *Streptococcus* Working Group**, Member, NCID, CDC
1999-2000 **Surveillance Integration Project Team**, Member, Office of the Director, CDC
1999-2000 **Electronic Laboratory-Based Reporting Group**, Member, Health Information and Surveillance Systems Board (HISSB), CDC
1996-2005 **Executive Committee of the Emerging Infections Network**, Member, Infectious Disease Society of America
1998-2002 **Public Health Informatics Fellowship Advisory Committee**, Member, CDC
1998 **Antibiotic Resistance Planning Workgroup**, Member, WA DOH
1997-2004 **Orders and Observations Technical Committee**, Member, Health Level Seven Standards Development Organization
1997-1998 **Antimicrobial Resistance Task Force**, Member Washington State Department of Health
1996-1997 **Standards and Liaison Working Group**, Member, Health Information and Surveillance Board, CDC
1996-1998 **Drug-Resistant *Streptococcus pneumoniae* Therapeutic Working Group**, Member and Contributing Author, CDC
1995-1996 **Committee on Electronic Laboratory Surveillance**, Member, CDC
1994-1996 **Drug-Resistant *Streptococcus pneumoniae* Working Group**, Member and Author of Proceedings, CDC
1990 **M.D. – M.P.H. Recruitment**, Coordinator, Baylor-UTSPH, Houston, TX
1989 **Vulnerable and Indigent Population Health Care Task Force**, Co-Chair, Texas Medical Center, Houston, TX
1986 **Physician's Task Force on Hunger in America**, Student Host, Houston, TX

Research and Investigations Summary

Epidemiologic Investigations, Evaluations, and Research (selected examples)

- 1991 *Mycobacterium haemophilum* in HIV-infected persons, New York City
- 1993 *Legionella cincinnatiensis* in renal transplant patients, Birmingham, AL
- 1994 Legionnaires' disease among cruise ship passengers, New York and Bermuda
- 1994 *Legionella pneumophila* in hospitalized patients, Bridgeport, CT
- 1995 Legionnaires' disease among square dancers, Burlington, IA
- 1995 Drug-resistant *Streptococcus pneumoniae* among children, Mexico City, MX
- 1996 *E. coli* O157:H7 from unpasteurized apple juice, Seattle, WA
- 1997 Hepatitis A infection among workers on a crab boat, Bering Sea
- 1997 *E. coli* O157:H7 in a residential trailer park, Yakima, WA
- 1997 Giardiasis from a municipal water supply, Grays Harbor, WA
- 1997 Evaluation of water quality data for surveillance of Giardiasis, Washington State.
- 1997-2000 Statewide Surveillance for antibiotic-resistant *Streptococcus pneumoniae*, Washington State, through the Antibiotic Resistance Surveillance Network (ARSN)
- 1998 Unexplained illness among workers in a correctional facility, Monroe, WA
- 1999 Evaluation of electronic laboratory-based reporting from hospitals in Hawaii
- 1998 *E. coli* O157:H7 at an elementary school, Kennewick, WA
- 1998-2002 Use of a national laboratory data repository for infectious diseases surveillance, collaboration with QuestDiagnostics, Inc.
- 2001 *Klebsiella* infections in a neonatal intensive care unit, Cairo, Egypt
- 2001 Fatal laboratory errors from anti-coagulation, Philadelphia, PA
- 2001-2002 Fatal *Clostridium* infections from contaminated musculoskeletal allografts, US
- 2001-2002 National response to bioterrorism-associated anthrax infections, US
- 2001-2002 Discriminant analysis to distinguish inhalational Anthrax from other causes of influenza-like illness, 2001-2002.
- 2001-2002 Development of an anthrax epidemiologic tool kit: a mechanism for promoting bioterrorism preparedness and rapid response
- 2002 Fatal meningitis from contaminated injectable medications prepared at compounding pharmacies
- 2002 Transmission of West Nile virus from blood and organ donors
- 2002 Determination of incidence of allograft-associated infections among patients receiving anterior cruciate ligament reconstruction in California
- 2003 Severe Acute Respiratory Syndrome (SARS) infections in Taiwan and US
- 2003 Investigation of Group A *Streptococcus* infection and death following implant of a cadaveric allograft tissue.
- 2003 Community-associated methicillin-resistant *Staphylococcus aureus* infections in Hawaii, supported by the CDC Office of Minority and Women's Health
- 2004 Transmission of methicillin-resistant *Staphylococcus aureus* infections among family members, Minnesota, supported by the CDC Antimicrobial Resistance Working Group.
- 2004 Transmission of lymphocytic choriomeningitis virus from an organ donor to four transplant recipients
- 2004 Transmission of rabies from an organ donor to four transplant recipients
- 2004 Investigation of Methicillin-Resistant *Staphylococcus aureus* transmission among members of the St. Louis Rams professional football team.
- 2004 Investigation of *Burkholderia cepacia* contamination of nationally-distributed commercially manufactured nose-spray.
- 2004 Determination of the magnitude of *Clostridium difficile*-associated disease in the US.
- 2004 Measurement of outcome differences among patients infected with multidrug-resistant *Acinetobacter* spp.
- 2005 Nationwide investigation of intravenous catheter flush syringes contaminated with *Pseudomonas fluorescens*.

2005	Investigation and control of transmission of Marburg virus, Uige, Angola.
2005	Determination of the cause for accidental distribution of H2N2, a non-circulating, pandemic strain of influenza.
2005	Investigation of <i>Ralstonia</i> -contaminated oxygen delivery devices.
2005	Evaluation of hand hygiene education among evacuees of Hurricanes Katrina and Rita residing in San Antonio Evacuation Centers
2005	Determination of chronic diseases burden on DMAT and other clinical providers at evacuation centers in San Antonio responding to Hurricanes Katrina and Rita.
2007-2014	Development of novel preparedness planning methods through use of Intervals, Triggers, and Actions framework for national response in the U.S.
2007-2009	Development of influenza diagnostic test devices for use at the point-of-care to detect seasonal and novel influenza infections
2008-2015	Development of a rapid influenza immunity test for detection of immune response to influenza infection and immunization
2009-2010	International response to 2009 H1N1 influenza pandemic.
2011-2013	Investigation of novel swine-origin triple-reassortant H3N2 influenza A (H3N2v) in the U.S. associated with agricultural fairs.
2013-2015	Emergency response to the emergence of avian influenza H7N9 in China.
2014	WHO Consultation to Kingdom of Saudi Arabia in response to Middle East Respiratory Syndrome (MERS)
2014-2015	Emergency response to Ebola virus disease, Sierra Leone and EOC-CDC Atlanta.
2014-2015	Emergency response to introduction of highly-pathogenic avian influenza A/H5N1 in North American wild birds and domestic poultry, joint response with USDA.
2016	Emergency response to highly-pathogenic avian influenza A/H7N8 in Indiana, joint response with USDA.
2015-2016	Emergency response to Zika virus in the Western Hemisphere, laboratory and epidemiologic support.
2016-17	Investigation of H7N2 among shelter cats in New York City (Epi-Aid)
2016-18	Response to surge in human cases of avian influenza A(H7N9) in China, risk assessment and vaccine development; SE Asia regional USG coordination and planning
2018-19	Response to influenza illness and death among migrants at processing facilities along the U.S.-Mexico border.
2019	Response to increased influenza B virus infections in Louisiana, epidemiologic investigation and deployment of mobile genomic sequencing unit
2020-23	Global response to COVID-19, CDC Incident Manager and CDC lead for national response (NRCC)
2022-24	U.S. response to Mpox, clades 2b and 1
2024	U.S. response to H5N1 avian influenza in dairy cattle

Publications in Peer-Reviewed Journals

h-Index Score: 68; Citations: 24,390, i10-index: 124 (Google Scholar – Feb 29, 2024)

1. **Moving cholera vaccines ahead of the epidemic curve.** Memish ZA, Blumberg L, Al-Maani AS, Baru R, Dube E, Gao GF, [Jernigan DB](#), Leo YS, Peiris M, Masud JH, McVernon J, Nonvignon J, Ogunsola FT, Reese H, Safdar RM, Ungchusak K, Wieler LH, Heymann D. *Lancet*. 2024 Jan 13;403(10422):127-129. doi: 10.1016/S0140-6736(23)02244-4. Epub 2023 Oct 17.
2. **Learning From COVID-19 to Improve Surveillance for Emerging Threats.** [Jernigan DB](#), George D, Lipsitch M. *Am J Public Health*. 2023 May;113(5):520-522. doi: 10.2105/AJPH.2023.307261. Epub 2023 Mar 16.
3. **Leveraging International Influenza Surveillance Systems and Programs during the COVID-**

- 19 Pandemic.** Marcenac P, McCarron M, Davis W, Igboh LS, Mott JA, Lafond KE, Zhou W, Sorrells M, Charles MD, Gould P, Arriola CS, Veguilla V, Guthrie E, Dugan VG, Kondor R, Gogstad E, Uyeki TM, Olsen SJ, Emukule GO, Saha S, Greene C, Bresee JS, Barnes J, Wentworth DE, Fry AM, [Jernigan DB](#), Azziz-Baumgartner E. *Emerg Infect Dis.* 2022 Dec;28(13):S26-S33.
4. **Influenza Activity in the US During the 2020-2021 Season.** Uyeki TM, Wentworth DE, [Jernigan DB](#). *JAMA.* 2021 Jun 8;325(22):2247-2248. doi: 10.1001/jama.2021.6125.
 5. **Preparing for the 2020-2021 Influenza Season.** Uyeki TM, Santoli J, [Jernigan DB](#). *JAMA.* 2020 Dec 8;324(22):2318-2319. doi:10.1001/jama.2020.21849
 6. **Systems thinking for health emergencies: use of process mapping during outbreak response.** Durski KN, Naidoo D, Singaravelu S, Shah AA, Djingarey MH, Formenty P, Ihekweazu C, Banjura J, Kebela B, Yinka-Ogunleye A, Fall IS, Eteng W, Vandi M, Keimbe C, Abubakar A, Mohammed A, Williams DE, Lamunu M, Briand S, Changa Changa JC, Minkoulou E, [Jernigan D](#), Lubambo D, Khalakdina A, Mamadu I, Talisuna A, Mbule Kadiobo A, Jambai A, Aylward B, Osterholm M. *BMJ Glob Health.* 2020 Oct;5(10):e003901. doi: 10.1136/bmjgh-2020-003901
 7. **Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season.** Grohskopf LA, Alyanak E, Broder KR, Blanton LH, Fry AM, [Jernigan DB](#), Atmar RL. *MMWR Recomm Rep.* 2020 Aug 21;69(8):1-24. doi: 10.15585/mmwr.rr6908a1.
 8. **Fifty Years of Influenza A(H3N2) Following the Pandemic of 1968.** Jester BJ, Uyeki TM, [Jernigan DB](#). *Am J Public Health.* 2020 May;110(5):669-676. doi: 10.2105/AJPH.2019.305557.
 9. **Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.** [Jernigan DB](#); CDC COVID-19 Response Team. *MMWR Morb Mortal Wkly Rep.* 2020 Feb 28;69(8):216-219. doi: 10.15585/mmwr.mm6908e1.
 10. **Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel Coronavirus Outbreak - United States, December 31, 2019-February 4, 2020.** Patel A, [Jernigan DB](#); 2019-nCoV CDC Response Team. *MMWR Morb Mortal Wkly Rep.* 2020 Feb 7;69(5):140-146. doi: 10.15585/mmwr.mm6905e1.
 11. **First Case of 2019 Novel Coronavirus in the United States.** Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team ([Jernigan D](#), Investigation Team Member). *N Engl J Med.* 2020 Mar 5;382(10):929-936. doi: 10.1056/NEJMoa2001191
 12. **Update: Influenza Activity - United States and Worldwide, May 19-September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine.** Epperson S, Davis CT, Brammer L, Abd Elal AI, Ajayi N, Barnes J, Budd AP, Burns E, Daly P, Dugan VG, Fry AM, Jang Y, Johnson SJ, Kniss K, Kondor R, Grohskopf LA, Gubareva L, Merced-Morales A, Sessions W, Stevens J, Wentworth DE, Xu X, [Jernigan D](#). *MMWR Morb Mortal Wkly Rep.* 2019 Oct 11;68(40):880-884.
 13. **Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2019-20 Influenza Season.** Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, [Jernigan DB](#). *MMWR Recomm Rep.* 2019 Aug 23;68(3):1-21.

14. **Update: Influenza Activity in the United States During the 2018-19 Season and Composition of the 2019-20 Influenza Vaccine.** Xu X, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, Brammer L, Budd AP, Burns E, Cummings CN, Garg S, Kondor R, Gubareva L, Kniss K, Nyanseor S, O'Halloran A, Rolfes M, Sessions W, Dugan VG, Fry AM, Wentworth DE, Stevens J, Jernigan D. *MMWR Morb Mortal Wkly Rep.* 2019 Jun 21;68(24):544-551.
15. **Update: Influenza Activity - United States, September 30, 2018-February 2, 2019.** Blanton L, Dugan VG, Abd Elal AI, Alabi N, Barnes J, Brammer L, Budd AP, Burns E, Cummings CN, Garg S, Garten R, Gubareva L, Kniss K, Kramer N, O'Halloran A, Reed C, Rolfes M, Sessions W, Taylor C, Xu X, Fry AM, Wentworth DE, Katz J, Jernigan D. *MMWR Morb Mortal Wkly Rep.* 2019 Feb 15;68(6):125-134.
16. **Influenza Activity – United States, September 30-December 1, 2018.** Budd AP, Abd Elal AI, Alabi N, Barnes J, Blanton L, Brammer L, Burns E, Cummings CN, Dugan VG, Garg S, Garten R, Grohskopf LA, Gubareva L, Kniss K, Kramer N, O'Halloran A, Sessions W, Taylor C, Wentworth DE, Xu X, Fry AM, Katz J, Jernigan D. *MMWR Morb Mortal Wkly Rep.* 2018 Dec 14;67(49):1369-1371.
17. **Historical and clinical aspects of the 1918 H1N1 pandemic in the United States.** Jester B, Uyeki TM, Jernigan DB, Tumpey TM. *Virology* 2019;527:32-37.
18. **Update: Influenza Activity - United States and Worldwide, May 20-October 13, 2018.** Chow EJ, Davis CT, Abd Elal AI, Alabi N, Azziz-Baumgartner E, Barnes J, Blanton L, Brammer L, Budd AP, Burns E, Davis WW, Dugan VG, Fry AM, Garten R, Grohskopf LA, Gubareva L, Jang Y, Jones J, Kniss K, Lindstrom S, Mustaqim D, Porter R, Rolfes M, Sessions W, Taylor C, Wentworth DE, Xu X, Zanders N, Katz J, Jernigan D. *MMWR Morb Mortal Wkly Rep.* 2018 Oct 26;67(42):1178-1185. doi: 10.15585/mmwr.mm6742a3
19. **100 Years of Medical Countermeasures and Pandemic Influenza Preparedness.** Jester BJ, Uyeki TM, Patel A, Koonin L, Jernigan DB. *Am J Public Health.* 2018 Nov;108(11):1469-1472. doi: 10.2105/AJPH.2018.304586. Epub 2018 Sep 25.
20. **Readiness for Responding to a Severe Pandemic 100 Years after 1918.** Jester B, Uyeki T, Jernigan D. *Am J Epidemiol.* 2018 Aug 9. doi: 10.1093/aje/kwy165. [Epub ahead of print]
21. **Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season.** Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. *MMWR Recomm Rep.* 2018 Aug 24;67(3):1-20. doi: 10.15585/mmwr.rr6703a1.
22. **Progress in Vaccine-Preventable and Respiratory Infectious Diseases-First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006-2015.** Schuchat A, Anderson LJ, Rodewald LE, Cox NJ, Hajjeh R, Pallansch MA, Messonnier NE, Jernigan DB, Wharton M. *Emerg Infect Dis.* 2018 Jul;24(7):1178-1187. doi: 10.3201/eid2407.171699
23. **Update: Influenza Activity in the United States During the 2017-18 Season and Composition of the 2018-19 Influenza Vaccine.** Garten R, Blanton L, Elal AIA, Alabi N, Barnes J, Biggerstaff M, Brammer L, Budd AP, Burns E, Cummings CN, Davis T, Garg S, Gubareva L, Jang Y, Kniss K, Kramer N, Lindstrom S, Mustaqim D, O'Halloran A, Sessions W, Taylor C, Xu X, Dugan VG, Fry AM, Wentworth DE, Katz J, Jernigan D. *MMWR Morb Mortal Wkly Rep.* 2018 Jun 8;67(22):634-642. doi:10.15585/mmwr.mm6722a4.
24. **Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.** Grohskopf LA, Sokolow LZ, Fry

- AM, Walter EB, Jernigan DB. MMWR Morb Mortal Wkly Rep. 2018 Jun 8;67(22):643-645. doi: 10.15585/mmwr.mm6722a5.
25. **Mapping of the US Domestic Influenza Virologic Surveillance Landscape.** Jester B, Schwerzmann J, Mustaquim D, Aden T, Brammer L, Humes R, Shult P, Shahngian S, Gubareva L, Xu X, Miller J, Jernigan D. Emerg Infect Dis. 2018 July 17;24(7). doi.org/10.3201/eid2407.180028
 26. **Update: Influenza Activity - United States, October 1, 2017-February 3, 2018.** Budd AP, Wentworth DE, Blanton L, Elal AIA, Alabi N, Barnes J, Brammer L, Burns E, Cummings CN, Davis T, Flannery B, Fry AM, Garg S, Garten R, Gubareva L, Jang Y, Kniss K, Kramer N, Lindstrom S, Mustaquim D, O'Halloran A, Olsen SJ, Sessions W, Taylor C, Xu X, Dugan VG, Katz J, Jernigan D. MMWR Morb Mortal Wkly Rep. 2018 Feb 16;67(6):169-179. doi: 10.15585/mmwr.mm6706a1.
 27. **Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness.** Rolfes MA, Foppa IM, Garg S, Flannery B, Brammer L, Singleton JA, Burns E, Jernigan D, Olsen SJ, Bresee J, Reed C. Influenza Other Respir Viruses. 2018 Jan;12(1):132-137. doi: 10.1111/irv.12486. Epub 2018 Feb 14.
 28. **Update: Influenza Activity - United States, October 1-November 25, 2017.** Dugan VG, Blanton L, Elal AIA, Alabi N, Barnes J, Brammer L, Burns E, Cummings CN, Davis T, Flannery B, Fry AM, Garg S, Garten R, Gubareva L, Jang Y, Kniss K, Kramer N, Lindstrom S, Mustaquim D, O'Halloran A, Olsen SJ, Sessions W, Taylor C, Trock S, Xu X, Wentworth DE, Katz J, Jernigan D. MMWR Morb Mortal Wkly Rep. 2017 Dec 8;66(48):1318-1326. doi: 10.15585/mmwr.mm6648a2.
 29. **Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2017-18 Influenza Season.** Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB. Am J Transplant. 2017 Nov;17(11):2970-2982. doi: 10.1111/ajt.14511.
 30. **Systematic Assessment of Multiple Routine and Near-Real Time Indicators to Classify the Severity of Influenza Seasons and Pandemics in the United States, 2003-04 through 2015-2016.** Biggerstaff M, Kniss K, Jernigan DB, Brammer L, Bresee J, Garg S, Burns E, Reed C. Am J Epidemiol. 2017 Oct 19. doi: 10.1093/aje/kwx334. [Epub ahead of print] PMID: 29053783
 31. **Update: Influenza Activity - United States and Worldwide, May 21-September 23, 2017.** Blanton L, Wentworth DE, Alabi N, Azziz-Baumgartner E, Barnes J, Brammer L, Burns E, Davis CT, Dugan VG, Fry AM, Garten R, Grohskopf LA, Gubareva L, Kniss K, Lindstrom S, Mustaquim D, Olsen SJ, Roguski K, Taylor C, Trock S, Xu X, Katz J, Jernigan D. MMWR Morb Mortal Wkly Rep. 2017 Oct 6;66(39):1043-1051. doi: 10.15585/mmwr.mm6639a3. PMID: 28981486
 32. **The Global Threat of Animal Influenza Viruses of Zoonotic Concern: Then and Now.** Widdowson MA, Bresee JS, Jernigan DB. J Infect Dis. 2017 Sep 15;216(suppl_4):S493-S498. doi: 10.1093/infdis/jix331. PMID: 28934463
 33. **Update: Increase in Human Infections with Novel Asian Lineage Avian Influenza A(H7N9) Viruses During the Fifth Epidemic - China, October 1, 2016-August 7, 2017.** Kile JC, Ren R, Liu L, Greene CM, Roguski K, Iuliano AD, Jang Y, Jones J, Thor S, Song Y, Zhou S, Trock SC, Dugan V, Wentworth DE, Levine MZ, Uyeki TM, Katz JM, Jernigan DB, Olsen SJ, Fry AM, Azziz-Baumgartner E, Davis CT. MMWR Morb Mortal Wkly Rep. 2017 Sep 8;66(35):928-932. doi: 10.15585/mmwr.mm6635a2. PMID: 28880856

34. **Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.** Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Bresee JS, Fry AM, Jernigan DB. MMWR Recomm Rep. 2017 Aug 25;66(2):1-20. doi: 10.15585/mmwr.rr6602a1. PMID: 28841201
35. **Update: Influenza Activity in the United States during the 2016-17 Season and Composition of the 2017-18 Influenza Vaccine.** Blanton L, Alabi N, Mustaquim D, Taylor C, Kniss K, Kramer N, Budd A, Garg S, Cummings CN, Chung J, Flannery B, Fry AM, Sessions W, Garten R, Xu X, Elal AIA, Gubareva L, Barnes J, Dugan V, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L. MMWR Morb Mortal Wkly Rep. 2017 Jun 30;66(25):668-676. doi: 10.15585/mmwr.mm6625a3. PMID: 28662019
36. **Novel influenza A viruses and pandemic threats.** Uyeki TM, Katz JM, Jernigan DB. Lancet. 2017 Jun 3;389(10085):2172-2174. doi: 10.1016/S0140-6736(17)31274-6. PMID: 28589883
37. **Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.** Sun X, Belser JA, Pulit-Penalzo JA, Creager HM, Guo Z, Jefferson SN, Liu F, York IA, Stevens J, Maines TR, Jernigan DB, Katz JM, Levine MZ, Tumpey TM. Virology. 2017 Aug;508:164-169. doi: 10.1016/j.virol.2017.05.010. Epub 2017 May 26. PMID: 28554058
38. **Community Mitigation Guidelines to Prevent Pandemic Influenza - United States, 2017.** Qualls N, Levitt A, Kanade N, Wright-Jegede N, Dopson S, Biggerstaff M, Reed C, Uzicanin A; CDC Community Mitigation Guidelines Work Group (Jernigan D, in Work Group). MMWR Recomm Rep. 2017 Apr 21;66(1):1-34.
39. **Increase in Human Infections with Avian Influenza A(H7N9) Virus During the Fifth Epidemic - China, October 2016-February 2017.** Iuliano AD, Jang Y, Jones J, Davis CT, Wentworth DE, Uyeki TM, Roguski K, Thompson MG, Gubareva L, Fry AM, Burns E, Trock S, Zhou S, Katz JM, Jernigan DB. MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):254-255.
40. **Evaluating the Impact of Pharmacies on Pandemic Influenza Vaccine Administration.** Schwerzmann J, Grainger SB, Jester B, Krahl D, Jernigan D, Bridges CB, Miller J. Disaster Med Public Health Prep. 2017 Oct 11(5):587-593.
41. **Update: Influenza Activity - United States, October 2, 2016-February 4, 2017.** Blanton L, Mustaquim D, Alabi N, Kniss K, Kramer N, Budd A, Garg S, Cummings CN, Fry AM, Bresee J, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, Jernigan D, Brammer L. MMWR Morb Mortal Wkly Rep. 2017 Feb 17;66(6):159-166.
42. **Improving the selection and development of influenza vaccine viruses - Report of a WHO informal consultation on improving influenza vaccine virus selection, Hong Kong SAR, China, 18-20 November 2015.** Hampson A, Barr I, Cox N, Donis RO, Siddhivinayak H, Jernigan D, Katz J, McCauley J, Motta F, Odagiri T, Tam JS, Waddell A, Webby R, Ziegler T, Zhang W. Vaccine. 2017 Feb 22;35(8):1104-1109. doi: 10.1016/j.vaccine.2017.01.018. Epub 2017 Jan 25. PMID: 28131392
43. **Evaluation of multiplex assay platforms for detection of influenza hemagglutinin subtype specific antibody responses.** Li ZN, Weber KM, Limmer RA, Horne BJ, Stevens J, Schwerzmann J, Wrammert J, McCausland M, Phipps AJ, Hancock K, Jernigan DB, Levine M, Katz JM, Miller JD. J Virol Methods. 2017 May;243:61-67.
44. **Update: Influenza Activity - United States, October 2-December 17, 2016.** Shang M, Blanton L, Kniss K, Mustaquim D, Alabi N, Barnes S, Budd A, Davlin SL, Kramer N, Garg S, Cummings

- CN, Flannery B, Fry AM, Grohskopf LA, Olsen SJ, Bresee J, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, [Jernigan D](#), Brammer L. *MMWR Morb Mortal Wkly Rep.* 2016 Dec 30;65(5051):1439-1444.
45. **CDC Grand Rounds: Modeling and Public Health Decision-Making.** Fischer LS, Santibanez S, Hatchett RJ, [Jernigan DB](#), Meyers LA, Thorpe PG, Meltzer MI. *MMWR Morb Mortal Wkly Rep.* 2016 Dec 9;65(48):1374-1377.
 46. **Reinvigorating Influenza Prevention in U.S. Adults 65 Years and Older.** Schaffner WS, Gravenstein S, Hopkins RH, [Jernigan DB](#). *Infect Dis Clin Pract* 2016;24:303–309.
 47. **Update: Influenza Activity - United States and Worldwide, May 22-September 10, 2016.** Budd A, Blanton L, Kniss K, Smith S, Mustaquim D, Davlin SL, Kramer N, Flannery B, Fry AM, Grohskopf LA, Olsen SJ, Bresee J, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, [Jernigan D](#), Brammer L. *MMWR Morb Mortal Wkly Rep.* 2016;65(37):1008-14.
 48. **Prevention and Control of Seasonal Influenza with Vaccines.** Grohskopf LA, Sokolow LZ, Broder KR, Olsen SJ, Karron RA, [Jernigan DB](#), Bresee JS. *MMWR Recomm Rep.* 2016 Aug 26;65(5):1-54.
 49. **Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014-2016 Ebola Epidemic.** Bell BP, Damon IK, [Jernigan DB](#), Kenyon TA, Nichol ST, O'Connor JP, Tappero JW. *MMWR Suppl.* 2016 Jul 8;65(3):4-11.
 50. **Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine.** Davlin SL, Blanton L, Kniss K, Mustaquim D, Smith S, Kramer N, Cohen J, Cummings CN, Garg S, Flannery B, Fry AM, Grohskopf LA, Bresee J, Wallis T, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, [Jernigan D](#), Brammer L. *MMWR Morb Mortal Wkly Rep.* 2016 Jun 10;65(22):567-75.
 51. **Update: Influenza Activity - United States, October 4, 2015-February 6, 2016.** Russell K, Blanton L, Kniss K, Mustaquim D, Smith S, Cohen J, Garg S, Flannery B, Fry AM, Grohskopf LA, Bresee J, Wallis T, Sessions W, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, [Jernigan D](#), Brammer L. *MMWR Morb Mortal Wkly Rep.* 2016 Feb 19;65(6):146-53.
 52. **Update: Influenza Activity - United States.** Smith S, Blanton L, Kniss K, Mustaquim D, Steffens C, Reed C, Bramley A, Flannery B, Fry AM, Grohskopf LA, Bresee J, Wallis T, Garten R, Xu X, Elal AI, Gubareva L, Barnes J, Wentworth DE, Burns E, Katz J, [Jernigan D](#), Brammer L. *MMWR Morb Mortal Wkly Rep.* 2015 Dec 11;64(48):1342-8.
 53. **Comparative analytical evaluation of the respiratory TaqMan Array Card with real-time PCR and commercial multi-pathogen assays.** Harvey JJ, Chester S, Burke SA, Ansbro M, Aden T, Gose R, Sciulli R, Bai J, DesJardin L, Benfer JL, Hall J, Smole S, Doan K, Popowich MD, St George K, Quinlan T, Halse TA, Li Z, Pérez-Osorio AC, Glover WA, Russell D, Reisdorf E, Whyte T Jr, Whitaker B, Hatcher C, Srinivasan V, Tatti K, Tondella ML, Wang X, Winchell JM, Mayer LW, [Jernigan D](#), Mawle AC. *J Virol Methods.* 2015 Nov 27. pii: S0166-0934(15)00381-X. doi: 10.1016/j.jviromet.2015.11.020.
 54. **Update: Influenza Activity--United States and Worldwide, May 24-September 5, 2015.** Blanton L, Kniss K, Smith S, Mustaquim D, Steffens C, Flannery B, Fry AM, Bresee J, Wallis T, Garten R, Xu X, Elal AI, Gubareva L, Wentworth DE, Burns E, Katz J, [Jernigan D](#), Brammer L. *MMWR Morb Mortal Wkly Rep.* 2015 Sep 18;64(36):1011-6.

55. **CDC's Early Response to a Novel Viral Disease, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), September 2012-May 2014.** Williams HA, Dunville RL, Gerber SI, Erdman DD, Pesik N, Kuhar D, Mason KA, Haynes L, Rotz L, St Pierre J, Poser S, Bunga S, Pallansch MA, Swerdlow DL; MERS-CoV Working Group (Jernigan DB, Working Group member). Public Health Rep. 2015 Jul-Aug;130(4):307-17.
56. **Strengthening the influenza vaccine virus selection and development process: Report of the 3rd WHO Informal Consultation for Improving Influenza Vaccine Virus Selection held at WHO headquarters, Geneva, Switzerland, 1-3 April 2014.** Ampofo WK, Azziz-Baumgartner E, Bashir U, Cox NJ, Fasce R, Giovanni M, Grohmann G, Huang S, Katz J, Mironenko A, Mokhtari-Azad T, Sasono PM, Rahman M, Sawanpanyalert P, Siqueira M, Waddell AL, Waiboci L, Wood J, Zhang W, Ziegler T; WHO Writing Group (Jernigan DB, contributor). Vaccine. 2015 Aug 26;33(36):4368-82.
57. **Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccine.** Appiah GD, Blanton L, D'Mello T, Kniss K, Smith S, Mustaquim D, Steffens C, Dhara R, Cohen J, Chaves SS, Bresee J, Wallis T, Xu X, Abd Elal AI, Gubareva L, Wentworth DE, Katz J, Jernigan D, Brammer L. MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):583-90.
58. **Update: influenza activity - United States, September 28, 2014-February 21, 2015.** D'Mello T, Brammer L, Blanton L, Kniss K, Smith S, Mustaquim D, Steffens C, Dhara R, Cohen J, Chaves SS, Finelli L, Bresee J, Wallis T, Xu X, Abd Elal AI, Gubareva L, Wentworth D, Villanueva J, Katz J, Jernigan D. MMWR Morb Mortal Wkly Rep. 2015 Mar 6;64(8):206-12.
59. **Estimated influenza illnesses and hospitalizations averted by vaccination--United States, 2013-14 influenza season.** Reed C, Kim IK, Singleton JA, Chaves SS, Flannery B, Finelli L, Fry A, Burns E, Gargiullo P, Jernigan D, Cox N, Bresee J; Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2014 Dec 12;63(49):1151-4.
60. **H7N9: Preparing for the Unexpected in Influenza.** Jernigan DB, Cox NJ. Annual Review of Medicine 2015;66:361-71.
61. **Updated preparedness and response framework for influenza pandemics.** Holloway R, Rasmussen SA, Zaza S, Cox NJ, Jernigan DB. MMWR 2014 Sep 26;63(RR-06):1-9.
62. **Response to Al-Husayni and Hassoun.** Uyeki TM, Jernigan DB. J Clin Virol. 2014 Sep;61(1):176-7.
63. **Rapid influenza diagnostic test use and antiviral prescriptions in outpatient settings pre- and post-2009 H1N1 pandemic.** Williams LO, Kupka NJ, Schmaltz SP, Barrett S, Uyeki TM, Jernigan DB. J Clin Virol. 2014 May;60(1):27-33.
64. **Outbreak of Variant Influenza A(H3N2) Virus in the United States.** Jhung MA, Epperson S, Biggerstaff M, Allen D, Balish A, Barnes N, Beaudoin A, Berman L, Bidol S, Blanton L, Blythe D, Brammer L, D'Mello T, Danila R, Davis W, de Fijter S, Diorio M, Durand LO, Emery S, Fowler B, Garten R, Grant Y, Greenbaum A, Gubareva L, Havers F, Haupt T, House J, Ibrahim S, Jiang V, Jain S, Jernigan D, Kazmierczak J, Klimov A, Lindstrom S, Longenberger A, Lucas P, Lynfield R, McMorrow M, Moll M, Morin C, Ostroff S, Page SL, Park SY, Peters S, Quinn C, Reed C, Richards S, Scheftel J, Simwale O, Shu B, Soyemi K, Stauffer J, Steffens C, Su S, Torso L, Uyeki TM, Vetter S, Villanueva J, Wong KK, Shaw M, Bresee JS, Cox N, Finelli L. Clin Infect Dis. 2013 Dec;57(12):1703-12.
65. **Human infections with influenza A(H3N2) variant virus in the United States, 2011-2012.** Epperson S, Jhung M, Richards S, Quinlisk P, Ball L, Moll M, Boulton R, Haddy L, Biggerstaff M,

- Brammer L, Trock S, Burns E, Gomez T, Wong KK, Katz J, Lindstrom S, Klimov A, Bresee JS, Jernigan DB, Cox N, Finelli L, and the Influenza A (H3N2)v Virus Investigation Team. Clin Infect Dis. 2013 Jul;57 Suppl 1:S4-S11.
66. **Estimates of the number of human infections with influenza A(H3N2) variant virus, United States, August 2011-April 2012.** Biggerstaff M, Reed C, Epperson S, Jhung MA, Gambhir M, Bresee JS, Jernigan DB, Swerdlow DL, Finelli L. Clin Infect Dis. 2013 Jul;57 Suppl 1:S12-5.
 67. **Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome.** Braden CR, Dowell SF, Jernigan DB, Hughes JM. Emerg Infect Dis. 2013 Jun;19(6):864-9.
 68. **Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics.** Reed C, Biggerstaff M, Finelli L, Koonin LM, Beauvais D, Uzicanin A, Plummer A, Bresee J, Redd SC, Jernigan DB. Emerg Infect Dis. 2013 Jan;19(1):85-91.
 69. **Pooling nasopharyngeal/throat swab specimens to increase testing capacity for influenza viruses by PCR.** Van TT, Miller J, Warshauer DM, Reisdorf E, Jernigan D, Humes R, Shult PA. J Clin Microbiol. 2012 Mar;50(3):891-6.
 70. **Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010.** WHO Writing Group (Jernigan DB, collaborator). Influenza Other Respir Viruses. 2012 Mar;6(2):142-52.
 71. **Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010).** Shrestha SS, Swerdlow DL, Borse RH, Prabhu VS, Finelli L, Atkins CY, Owusu-Edusei K, Bell B, Mead PS, Biggerstaff M, Brammer L, Davidson H, Jernigan D, Jhung MA, Kamimoto LA, Merlin TL, Nowell M, Redd SC, Reed C, Schuchat A, Meltzer MI. Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S75-82.
 72. **Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic response.** Jernigan DB, Lindstrom SL, Johnson JR, Miller JD, Hoelscher M, Humes R, Shively R, Brammer L, Burke SA, Villanueva JM, Balish A, Uyeki T, Mustaqim D, Bishop A, Handsfield JH, Astles R, Xu X, Klimov AI, Cox NJ, Shaw MW. Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S36-43.
 73. **Epidemiology of 2009 pandemic influenza A (H1N1) in the United States.** Jhung MA, Swerdlow D, Olsen SJ, Jernigan D, Biggerstaff M, Kamimoto L, Kniss K, Reed C, Fry A, Brammer L, Gindler J, Gregg WJ, Bresee J, Finelli L. Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S13-26.
 74. **Prevention of community-associated methicillin-resistant Staphylococcus aureus infection among Asian/Pacific Islanders: a qualitative assessment.** Ciccarone RM, Kim M, Tice AD, Nakata M, Effler P, Jernigan DB, Cardo DM, Sinkowitz-Cochran RL. Hawaii Med J. 2010 Jun;69(6):142-4.
 75. **Community-driven standards-based electronic laboratory data-sharing networks.** Zarcone P, Nordenberg D, Meigs M, Merrick U, Jernigan D, Hinrichs SH. Public Health Rep. 2010 May-Jun;125 Suppl 2:47-56.
 76. **Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009.** Reed C, Angulo FJ, Swerdlow DL, Lipsitch M, Meltzer MI, Jernigan D, Finelli L. Emerg Infect Dis. 2009 Dec;15(12):2004-7.

77. **Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.** Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, Jasuja S, Deutscher M, Chen S, Walker JD, Duchin JS, Lett S, Soliva S, Wells EV, Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM, Bridges CB, Finelli L, and the 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team (Jernigan DB Team member). *N Engl J Med.* 2009 Nov 12;361(20):1935-44.
78. **Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.** Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivaller P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ. *Science.* 2009 Jul 10;325(5937):197-201.
79. **Emergence of a novel swine-origin influenza A (H1N1) virus in humans.** Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (Jernigan DB Team member), Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges CB, Uyeki TM. *N Engl J Med.* 2009 Jun 18;360(25):2605-15.
80. **Community strains of methicillin-resistant *Staphylococcus aureus* as potential cause of healthcare-associated infections, Uruguay, 2002-2004.** Benoit SR, Estivariz C, Mogdasy C, Pedreira W, Galiana A, Galiana A, Bagnulo H, Gorwitz R, Fosheim GE, McDougal LK, Jernigan D. *Emerg Infect Dis.* 2008 Aug;14(8):1216-23.
81. **Outbreak of *Serratia marcescens* bloodstream and central nervous system infections after interventional pain management procedures.** Cohen AL, Ridpath A, Noble-Wang J, Jensen B, Peterson AM, Arduino M, Jernigan D, Srinivasan A. *Clin J Pain.* 2008 Jun;24(5):374-80.
82. **National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents.** Cohen AL, Budnitz DS, Weidenbach KN, Jernigan DB, Schroeder TJ, Shehab N, Pollock DA. *J Pediatr.* 2008 Mar;152(3):416-21.
83. **Methamphetamine use and methicillin-resistant *Staphylococcus aureus* skin infections.** Cohen AL, Shuler C, McAllister S, Fosheim GE, Brown MG, Abercrombie D, Anderson K, McDougal LK, Drenzek C, Arnold K, Jernigan D, Gorwitz R. *Emerg Infect Dis.* 2007 Nov;13(11):1707-13.
84. **Chronic disease and disasters medication demands of Hurricane Katrina evacuees.** Jung MA, Shehab N, Rohr-Allegri C, Pollock DA, Sanchez R, Guerra F, Jernigan DB. *Am J Prev Med.* 2007 Sep;33(3):207-10.
85. **Invasive group-A streptococcal infection in an allograft recipient. A case report.** Lee EH, Ferguson D, Jernigan D, Greenwald M, Coté T, Bos JE, Guarner J, Zaki S, Schuchat A, Beall B, Srinivasan A. *J Bone Joint Surg Am.* 2007 Sep;89(9):2044-7.
86. **A multistate outbreak of *Serratia marcescens* bloodstream infection associated with contaminated intravenous magnesium sulfate from a compounding pharmacy.** Sunenshine RH, Tan ET, Terashita DM, Jensen BJ, Kacica MA, Sickbert-Bennett EE, Noble-Wang JA, Palmieri MJ, Bopp DJ, Jernigan DB, Kazakova S, Bresnitz EA, Tan CG, McDonald LC. *Clin Infect Dis.* 2007 Sep 1;45(5):527-33.

87. **Methicillin-resistant *Staphylococcus aureus* infections among healthy full-term newborns.** James L, Gorwitz RJ, Jones RC, Watson JT, Hageman JC, Jernigan DB, Lord Y, Caballes N, Cortes C, Golash RG, Price JS, Gerber SI. Arch Dis Child Fetal Neonatal Ed. 2008 Jan;93(1):F40-4.
88. **Multidrug-resistant *Acinetobacter* infection mortality rate and length of hospitalization.** Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, Cosgrove SE, Anderson A, Carnell J, Jernigan DB, Kleinbaum DG, Perl TM, Standiford HC, Srinivasan A. Emerg Infect Dis. 2007 Jan;13(1):97-103.
89. ***Staphylococcus aureus*-associated skin and soft tissue infections in ambulatory care.** McCaig LF, McDonald LC, Mandal S, Jernigan DB. Emerg Infect Dis. 2006 Nov;12(11):1715-23.
90. **An Outbreak of *Burkholderia cepacia* Associated With Contamination of Albuterol and Nasal Spray.** Estivariz CF, Bhatti LI, Pati R, Jensen B, Arduino MJ, Jernigan D, Lipuma JJ, Srinivasan A. Chest. 2006 Nov;130(5):1346-53.
91. **Emergence of community-associated methicillin resistant *Staphylococcus aureus* in Hawaii, 2001-2003.** Estivariz CF, Park SY, Hageman JC, Dvorin J, Melish MM, Arpon R, Coon P, Slavish S, Kim M, McDougal LK, Jensen B, McAllister S, Lonsway D, Killgore G, Effler PE, Jernigan DB. J Infect. 2007 Apr;54(4):349-57.
92. **Community-associated methicillin-resistant *Staphylococcus aureus* skin infections in a religious community.** Coronado F, Nicholas JA, Wallace BJ, Kohlerschmidt DJ, Musser K, Schoonmaker-Bopp DJ, Zimmerman SM, Boller AR, Jernigan DB, Kacica MA. Epidemiol Infect 2006;Jul 26:1-10.
93. **Emerging infectious disease outbreaks: old lessons and new challenges for obstetrician-gynecologists.** Jamieson DJ, Ellis JE, Jernigan DB, Treadwell TA. Am J Obstet Gynecol. 2006;194(6):1546-55.
94. **Transmission of lymphocytic choriomeningitis virus by organ transplantation.** Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, Comer JA, Guarner J, Paddock CD, DeMeo DL, Shieh WJ, Erickson BR, Bandy U, DeMaria A Jr, Davis JP, Delmonico FL, Pavlin B, Likos A, Vincent MJ, Sealy TK, Goldsmith CS, Jernigan DB, Rollin PE, Packard MM, Patel M, Rowland C, Helfand RF, Nichol ST, Fishman JA, Ksiazek T, Zaki SR; LCMV in Transplant Recipients Investigation Team. N Engl J Med. 2006 May 25;354(21):2235-49.
95. **Severe community-acquired pneumonia due to *Staphylococcus aureus*, 2003-04 influenza season.** Hageman JC, Uyeki TM, Francis JS, Jernigan DB, Wheeler JG, Bridges CB, Barenkamp SJ, Sievert DM, Srinivasan A, Doherty MC, McDougal LK, Killgore GE, Lopatin UA, Coffman R, MacDonald JK, McAllister SK, Fosheim GE, Patel JB, McDonald LC. Emerg Infect Dis. 2006 Jun;12(6):894-9
96. ***Clostridium difficile* infection in patients discharged from US short-stay hospitals, 1996-2003.** McDonald LC, Owings M, Jernigan DB. Emerg Infect Dis. 2006 Mar;12(3):409-15.
97. **Emerging infections and pregnancy: West Nile virus, monkeypox, severe acute respiratory syndrome, and bioterrorism.** Jamieson DJ, Jernigan DB, Ellis JE, Treadwell TA. Clin Perinatol. 2005 Sep;32(3):765-76.
98. **A new old opportunity for preventing serious Group A streptococcal infections.** Levine OS, Van Beneden CA, Jernigan DB. Clin Infect Dis. 2005 Aug 1;41(3):343-4.

99. **Neonatal sepsis in Egypt associated with bacterial contamination of glucose-containing intravenous fluids.** Moore KL, Kainer MA, Badrawi N, Afifi S, Wasfy M, Bashir M, Jarvis WR, Graham TW, el-Kholy A, Gipson R, Jernigan DB, Mahoney F. *Pediatr Infect Dis J*. 2005 Jul;24(7):590-4.
100. **Investigation of postoperative allograft-associated infections in patients who underwent musculoskeletal allograft implantation.** Crawford C, Kainer M, Jernigan D, Banerjee S, Friedman C, Ahmed F, Archibald LK. *Clin Infect Dis*. 2005 Jul 15;41(2):195-200.
101. **Methicillin-resistant *Staphylococcus aureus* hospitalizations, United States.** Kuehnert MJ, Hill HA, Kupronis BA, Tokars JI, Solomon SL, Jernigan DB. *Emerg Infect Dis*. 2005 Jun;11(6):868-72.
102. **A national survey of severe influenza-associated complications among children and adults, 2003-2004.** Podewils LJ, Liedtke LA, McDonald LC, Hageman JC, Strausbaugh LJ, Fischer TK, Jernigan DB, Uyeki TM, Kuehnert MJ; Infectious Diseases Society of America Emerging Infections Network. *Clin Infect Dis*. 2005 Jun 1;40(11):1693-6.
103. **Transmission of rabies virus from an organ donor to four transplant recipients.** Srinivasan A, Burton EC, Kuehnert MJ, Rupprecht C, Sutker WL, Ksiazek TG, Paddock CD, Guarner J, Shieh WJ, Goldsmith C, Hanlon CA, Zoretic J, Fischbach B, Niezgoda M, El-Feky WH, Orciari L, Sanchez EQ, Likos A, Klintmalm GB, Cardo D, LeDuc J, Chamberland ME, Jernigan DB, Zaki SR; Rabies in Transplant Recipients Investigation Team. *N Engl J Med*. 2005 Mar 17;352(11):1103-11.
104. **A clone of methicillin-resistant *Staphylococcus aureus* among professional football players.** Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, Boo T, McAllister S, Anderson J, Jensen B, Dodson D, Lonsway D, McDougal LK, Arduino M, Fraser VJ, Killgore G, Tenover FC, Cody S, Jernigan DB. *N Engl J Med*. 2005 Feb 3;352(5):468-75.
105. **SARS clinical features, United States, 2003.** Srikantiah P, Charles MD, Reagan S, Clark TA, Pletz MW, Patel PR, Hoekstra RM, Lingappa J, Jernigan JA, Fischer M, for the CDC SARS Clinical Investigation Team (Jernigan DB Team member). *Emerg Infect Dis*. 2005;11(1):135-138.
106. **Foundations of the severe acute respiratory syndrome preparedness and response plan for healthcare facilities.** Srinivasan A, McDonald LC, Jernigan D, Helfand R, Ginsheimer K, Jernigan J, Chiarello L, Chinn R, Parashar U, Anderson L, Cardo D; SARS Healthcare Preparedness and Response Plan Team. *Infect Control Hosp Epidemiol*. 2004;25(12):1020-5.
107. **Rapid evaluation of risk of white particulate matter in blood components by a statewide survey of transfusion reactions.** Iwamoto M, Curns AT, Blake PA, Jernigan DB, Holman RC, Lance-Parker SE, Chamberland ME, Kuehnert MJ. *Transfusion*. 2004 Jul;44(7):967-72.
108. **Clostridium infections associated with musculoskeletal-tissue allografts.** Kainer MA, Linden JV, Whaley DN, Holmes HT, Jarvis WR, Jernigan DB, Archibald LK. *N Engl J Med*. 2004 Jun 17;350(25):2564-71.
109. **SARS in healthcare facilities, Toronto and Taiwan.** McDonald LC, Simor AE, Su IJ, Maloney S, Ofner M, Chen KT, Lando JF, McGeer A, Lee ML, Jernigan DB. *Emerg Infect Dis*. 2004 May;10(5):777-81.

110. **The anthrax epidemiologic tool kit: an instrument for public health preparedness.** Reissman DB, Steinberg EB, Magri JM, Jernigan DB. Biosecurity and Bioterrorism: Biodefense Strategy, Practice, and Science. 2003;1(2):111-6.
111. **Role of infectious diseases consultants in management of antimicrobial use in hospitals.** Sunenshine RH, Liedtke LA, Jernigan DB, Strausbaugh LJ, and the Infectious Diseases Society of America Emerging Infections Network. Clin Infect Dis 2004;38(7):939-42.
112. **Lack of SARS transmission among healthcare workers, United States.** Park BJ, Peck AJ, Kuehnert MJ, Newbern C, Smelser C, Comer JA, Jernigan DB, McDonald LC. Emerg Infect Dis 2004;10(2):244-8.
113. **Fatal West Nile virus encephalitis in a renal transplant recipient.** Cushing MM, Brat DJ, Mosunjac MI, Hennigar RA, Jernigan DB, Lanciotti R, Petersen LR, Goldsmith C, Rollin PE, Shieh WJ, Guarner J, Zaki SR. Am J Clin Pathol 2004;121(1):26-31.
114. **Transmission of West Nile virus from an organ donor to four transplant recipients.** Iwamoto M, Jernigan DB, Guasch A, Trepka MJ, Blackmore CG, Hellinger WC, Pham SM, Zaki S, Lanciotti RS, Lance-Parker S, DiazGranados CA, Winquist AG, Perlino CA, Wiersma S, Hillyer KL, Goodman JL, Marfin AA, Chamberland ME, Petersen LR, and the West Nile Virus in Transplant Recipients Investigation Team. N Engl J Med. 2003;348(22):2196-203.
115. **The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax.** Shieh WJ, Gaurner J, Paddock C, Greer P, Tatti K, Fischer M, Layton M, Philips M, Bresnitz E, Quinn CP, Popovic T, Perkins BA, Zaki SR, and the Anthrax Bioterrorism Investigation Team (Jernigan DB team member). Am J Pathol 2003 Nov; 163(5):1901-1910.
116. **Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses.** Kuehnert M, Doyle T, Hill H, Bridges C, Jernigan J, Dull P, Reissman D, Ashford D, Jernigan DB. Clin Infect Dis. 2003 Feb 1;36(3):328-36.
117. **Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.** Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA, Butler JC, Cetron M, Cohen M, Doyle T, Fischer M, Greene C, Griffith KS, Guarner J, Hadler JL, Hayslett JA, Meyer R, Petersen LR, Phillips M, Pinner R, Popovic T, Quinn CP, Reefhuis J, Reissman D, Rosenstein N, Schuchat A, Shieh WJ, Siegal L, Swerdlow DL, Tenover FC, Traeger M, Ward JW, Weisfuse I, Wiersma S, Yeskey K, Zaki S, Ashford DA, Perkins BA, Ostroff S, Hughes J, Fleming D, Koplan JP, Gerberding JL, and the National Anthrax Epidemiologic Investigation Team. Emerging Infectious Diseases 2002;8:1019-28.
118. **Automatic Electronic Laboratory-Based Reporting of Notifiable Infectious Diseases at a Large Health System.** Panackal AA, M'ikanatha NM, Tsui FC, McMahon J, Wagner MM, Dixon BW, Zubieta J, Phelan M, Morgan J, Jernigan DB, Pasculle W, Rankin JT, Hajjeh RA, Harrison LH. Emerging Infectious Diseases. 2002;8(7):685-91.
119. **Decision-making on the use of antimicrobial prophylaxis for dental procedures: a survey of infectious disease consultants and review.** Lockhart PB, Brennan MT, Fox PC, Norton HJ, Jernigan DB, Strausbaugh LJ. Clinical Infectious Diseases 2002;34(12):1621-6.
120. **Influenza in Acute Care.** Strausbaugh LJ, Bridges CB, Jernigan DB, Liedtke LA, and the Infectious Diseases Society of America Emerging Infections Network. Infections in Medicine 2002;19(7):310-17.

121. **Electronic laboratory-based reporting: opportunities and challenges for surveillance.** Jernigan DB. Emerg Infect Dis. 2001;7(3 Suppl):538.
122. **Treating cardiovascular disease with antimicrobial agents: a survey of knowledge, attitudes and practices among U.S. physicians.** Gimenez-Sanchez F, Butler JC, Jernigan DB, Strausbaugh LJ, Slemp CC, Perilla MJ, Dowell SF. Clinical Infectious Diseases, 2001;33(2):171-6.
123. **Sentinel surveillance as an alternative approach for monitoring antibiotic-resistant invasive pneumococcal disease in Washington State.** Jernigan DB, Kargacin L, Poole A, Kobayashi J. American Journal of Public Health 2001;91(1):142-5.
124. **Long-Term Suppressive Antimicrobial Therapy for Intravascular Device-Related Infections.** Baddour LM and the Infectious Diseases Society of America's Emerging Infections Network (Jernigan D, contributor). The American Journal of the Medical Sciences 2001;322(4):209-212.
125. **National shortages of antimicrobial agents: results of 2 surveys from the Infectious Diseases Society of America Emerging Infections Network.** Strausbaugh LJ, Jernigan DB, Liedtke LA. Clin Infect Dis. 2001 Nov 1;33(9):1495-501.
126. **Management of patients with invasive group A streptococcal illness and their household contacts: experience of infectious diseases consultants.** Levine OS, Jernigan DB, Liedtke L, Van Beneden C, Strausbaugh LJ. Infectious Diseases in Clinical Practice, 2001;10(1):14-16.
127. **Electronic laboratory-based reporting for public health.** Pinner RW, Jernigan DB, Sutliff SM. Military Medicine 2000; 165(7 Suppl 2):20-4.
128. **A novel multi-resistant *Streptococcus pneumoniae* serogroup 19 clone from Washington State identified by pulsed-field gel electrophoresis and restriction fragment length patterns.** Luna BA, Jernigan DB, Tice A, Kellner JD, Roberts MC. Journal of Clinical Microbiology 2000;38(4):1575-80.
129. **Statewide system of electronic notifiable disease reporting from clinical laboratories: comparing automated reporting with conventional methods.** Effler P, Ching-Lee M, Bogard A, Ieong MC, Nekomoto T, Jernigan DB. JAMA 1999;282(19):1845-50.
130. **Acute otitis media: management and surveillance in the era of pneumococcal resistance – a report from the Drug-Resistant *Streptococcus pneumoniae* Therapeutic Working Group (DRSPTWG).** Dowell SF, Butler JC, Giebink GS, Jacobs MR, Jernigan DB, Musher DM, Rakowsky A, Schwartz B. Pediatric Infectious Disease Journal 1999;18(1):1-9.
131. **A recurrent outbreak of nosocomial Legionnaires' disease detected by urinary antigen testing: evidence for long-term colonization of a plumbing system.** Lepine LA, Jernigan DB, Butler JC, Pruckler JM, Benson RF, Kim G, Hadler JL, Cartter ML, Fields BS. Infection Control and Hospital Epidemiology 1998;19(12):905-10.
132. **Resistance to antimicrobial chemotherapy: a prescription for research and action.** Levin BR, Antia R, Berliner E, Bloland P, Bonhoeffer S, Cohen M, DeRouin T, Fields P, Jafari H, Jernigan D, Lipsitch M, McGowen J, Mead P, Nowak M, Porco T, Sykora P, Simonsen L, Spitznagel J, Tauxe R, Tenover F. American Journal of Medical Science 1998;315(2):87-94.

133. **The Emerging Infections Network: a new venture for the Infectious Diseases Society of America. Executive Committee of the Infectious Diseases Society of America Emerging Infections Network.** (Jernigan D, contributor). *Clinical Infectious Diseases* 1997;25:34-6.
134. **Perspectives in fatal epidemics.** Butler J, Kilmarx P, Jernigan DB, Ostroff SM. *Infectious Disease Clinics of North America* 1996;10:917-37.
135. **Minimizing the impact of drug-resistant *Streptococcus pneumoniae* (DRSP): a strategy from the DRSP Working Group.** Jernigan DB, Cetron MS, Breiman RF. *JAMA* 1996;275:206-9.
136. **Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa.** Jernigan DB, Hofmann J, Cetron MS, Genese CA, Nuorti JP, Fields BS, Benson RF, Carter RJ, Edelstein PH, Guerrero IC, Paul SM, Lipman HB, Breiman RF. *Lancet* 1996;347:494-9.
137. **Action plan for drug-resistant *Streptococcus pneumoniae*.** Cetron MS, Jernigan DB, Breiman RF. *Emerging Infectious Diseases* 1995;1(2):64-5.
138. **Pulmonary infection due to *Legionella cinchonae* in renal transplant recipients: two cases and implications for laboratory diagnosis.** Jernigan DB, Istorico Sanders L, Waites KB, Brookings ES, Benson RF, Pappas PG. *Clinical Infectious Diseases* 1994;18:385-389.
139. **Clinical and epidemiologic characteristics of *Mycobacterium haemophilum*, an emerging pathogen in immunocompromised patients.** Straus WL, Ostroff SM, Jernigan DB, Sordillo E, Armstrong D, Kiehn T, Boone N, Schneider N, Kilburn J, Silcox V, Good RC. *Annals of Internal Medicine* 1994;120:118-125.
140. **Cefamandole levels during thoracoabdominal aneurysm surgery.** Harris RL, Yuk JH, Cribari C, Jernigan DB, Coselli JS, Safi HJ, Crawford ES. *J Vasc Surg* 1991;14:668-672.

Publications – Book Chapters

1. **Future Surveillance for Epidemic and Pandemic Diseases: A 2023 Perspective.** Geneva: World Health Organization; 2023. Jernigan D, Vice-Chair of WHO Strategic and Technical Advisory Group on Infectious Hazards with Pandemic and Epidemic Potential (STAG-IH). <https://www.who.int/publications/i/item/9789240080959>.
2. **Exploring Lessons Learned from a Century of Outbreaks: Readiness for 2030.** National Academies of Science, Engineering, and Medicine. 2019. Washington, DC: The National Academies Press. doi: <https://doi.org/10.17226/25391>. Jernigan D, member Workshop Planning Committee.
3. **Emerging Influenza Viruses**, Uyeki T, Jernigan D in Chapter 14: Emerging and Re-emerging Infectious Disease Threats, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Elsevier Inc, 2015.
4. **Human Influenza: One Health, One World**, Jernigan DB, Cox NJ. In: Textbook of Influenza, 2nd Edition, edited by Webster RG, Monto AS, Braciale TJ, Lamb RA. Hoboken, NJ, Wiley-Blackwell Publishing, September 2013.
5. **Pandemic Influenza in North America.** Jernigan D. In: Pandemic Influenza, 2nd Edition, edited by Van-Tam J, Sellwood C. London, 2012 CABI Publishing, February 2013.
6. **Emergence of MRSA in the Community.** Cohen AL, Gorwitz R, Jernigan DB. In: Antimicrobial Resistance and Implications for the 21st Century, part of the series Emerging Infectious Diseases of the 21st Century. Edited by Fong, I.W. and Drlica, K. New York, NY: Springer Publishing, 2008.

7. **Emerging Infections.** Strausbaugh LJ, Jernigan DB. In: Infectious Diseases, 3rd Edition. Edited by Sherwood L. Gorbach, John B. Bartlett, and Neil R. Blacklow, Philadelphia, PA, WB Saunders Co Publishing, 2004.
8. **Data Standards.** Jernigan DB, Davies JA, Sim A., In: Public health informatics and information systems. Edited by O'Carroll P, Yasnoff W, Ward E, Ripp L, Martin E. Gaithersburg, MD, Aspen Publishing, 2002.

Invited Presentations, Conference Abstracts, Government Reports, and Public Notifications

Documents from 1991 to 2024 are available by request.